Scholars@Duke
James Emmett Herndon II

James Emmett Herndon II

Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
james.herndon@duke.edu
Duke Box 2717, Durham, NC 27710
2424 Erwin Road, 8020 Hock Plaza, Durham, NC 27705

Selected Publications

Automated segmentation of ablated lesions using deep convolutional neural networks: A basis for response assessment following laser interstitial thermal therapy.

Journal Article Neuro Oncol · June 3, 2024 BACKGROUND: Laser interstitial thermal therapy (LITT) of intracranial tumors or radiation necrosis enables tissue diagnosis, cytoreduction, and rapid return to systemic therapies. Ablated tissue remains in situ, resulting in characteristic post-LITT edema ... Full text Link to item Cite

Variation in Oral Board Examination Accommodations Among Specialties.

Journal Article JAMA Netw Open · May 1, 2024 IMPORTANCE: Board certification can have broad implications for candidates' career trajectories, and prior research has found sociodemographic disparities in pass rates. Barriers in the format and administration of the oral board examinations may dispropor ... Full text Open Access Link to item Cite

A blinded study using laser induced endogenous fluorescence spectroscopy to differentiate ex vivo spine tumor, healthy muscle, and healthy bone.

Journal Article Sci Rep · January 22, 2024 Ten patients undergoing surgical resection for spinal tumors were selected. Samples of tumor, muscle, and bone were resected, de-identified by the treating surgeon, and then scanned with the TumorID technology ex vivo. This study investigates whether Tumor ... Full text Open Access Link to item Cite

Comparing Knowledge and Perceptions of Palliative Care Among Neuro-Oncology Patients, Caregivers, and Providers to a Representative U.S. Sample

Conference American Journal of Hospice and Palliative Medicine · January 1, 2024 Background: Primary brain tumors (PBTs) pose a significant health challenge, affecting patients and their caregivers. While early integration of palliative care (PC) has shown benefits in advanced cancer, its integration for PBT patients, particularly glio ... Full text Cite

Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: a randomized trial.

Journal Article Eur Heart J · December 7, 2023 AIMS: The most appropriate timing of exercise therapy to improve cardiorespiratory fitness (CRF) among patients initiating chemotherapy is not known. The effects of exercise therapy administered during, following, or during and following chemotherapy were ... Full text Link to item Cite

Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.

Journal Article Lung Cancer · December 2023 OBJECTIVES: To assess the prevalence of lung cancer in Lung-RADS category 4 patients, and to elucidate if clinical or imaging features help differentiate benign lesions from lung cancer. MATERIALS/METHODS: A retrospective review of lung cancer screening (L ... Full text Link to item Cite

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

Journal Article Lancet Child Adolesc Health · July 2023 BACKGROUND: Outcomes of recurrent paediatric high-grade glioma are poor, with a median overall survival of less than 6 months. Viral immunotherapy, such as the polio-rhinovirus chimera lerapolturev, is a novel approach for treatment of recurrent paediatric ... Full text Link to item Cite

CD155 is a putative therapeutic target in medulloblastoma.

Journal Article Clin Transl Oncol · March 2023 BACKGROUND: Medulloblastoma is the most common pediatric malignant brain tumor, consisting of four molecular subgroups (WNT, SHH, Group 3, Group 4) and 12 subtypes. Expression of the cell surface poliovirus receptor (PVR), CD155, is necessary for entry of ... Full text Link to item Cite

Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.

Journal Article Sci Transl Med · February 8, 2023 D2C7-immunotoxin (IT), a dual-specific IT targeting wild-type epidermal growth factor receptor (EGFR) and mutant EGFR variant III (EGFRvIII) proteins, demonstrates encouraging survival outcomes in a subset of patients with glioblastoma. We hypothesized tha ... Full text Link to item Cite

Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.

Conference Breast Cancer Res Treat · January 2023 PURPOSE: Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never bee ... Full text Link to item Cite

Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery.

Journal Article Adv Radiat Oncol · 2023 PURPOSE: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors following HF-S ... Full text Link to item Cite

ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination.

Journal Article Neurooncol Adv · 2023 BACKGROUND: Medulloblastoma is the most common malignant pediatric brain tumor, and leptomeningeal dissemination (LMD) of medulloblastoma both portends a poorer prognosis at diagnosis and is incurable at recurrence. The biological mechanisms underlying LMD ... Full text Link to item Cite

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.

Journal Article Support Care Cancer · April 2022 PURPOSE: At diagnosis and throughout the disease course, patients with high-grade glioma (HGG) experience a diminished quality of life (QOL) and increased fatigue. Naltrexone, an orally semisynthetic opiate antagonist, is FDA-approved for the treatment of ... Full text Link to item Cite

Availability and role of clinical pharmacists in ambulatory neuro-oncology.

Journal Article Neurooncol Pract · February 2022 BACKGROUND: Outpatient clinics treating neuro-oncology patients are becoming more multidisciplinary. Utilization of all team members is critical for the holistic care of these complex patients. Specifically, the role of clinical pharmacist (CP) in the ambu ... Full text Link to item Cite

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.

Journal Article Clin Cancer Res · January 1, 2022 Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action-based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial ... Full text Link to item Cite

Prognostic significance of a complement factor H autoantibody in early stage NSCLC.

Journal Article Cancer Biomark · 2022 BACKGROUND: Biomarkers that predict which patients with early stage NSCLC will develop recurrent disease would be of clinical value. We previously discovered that an autoantibody to a complement regulatory protein, complement factor H (CFH), is associated ... Full text Open Access Link to item Cite

Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.

Journal Article Adv Radiat Oncol · 2022 PURPOSE: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These pat ... Full text Link to item Cite

Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.

Journal Article Front Oncol · 2022 BACKGROUND: There is a concern that HER2-directed systemic therapies, when administered concurrently with stereotactic radiosurgery (SRS), may increase the risk of radiation necrosis (RN). This study explores the impact of timing and type of systemic thera ... Full text Link to item Cite

Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases.

Journal Article Neurooncol Adv · 2022 BACKGROUND: Improved survival for patients with brain metastases has been accompanied by a rise in tumor recurrence after stereotactic radiotherapy (SRT). Laser interstitial thermal therapy (LITT) has emerged as an effective treatment for SRT failures as a ... Full text Link to item Cite

Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial.

Journal Article J Cachexia Sarcopenia Muscle · December 2021 BACKGROUND: Poor cardiorespiratory fitness (CRF) is a cardinal feature of post-treatment primary lung cancer. The most effective exercise therapy regimen to improve CRF has not been determined. METHODS: In this parallel-group factorial randomized controlle ... Full text Link to item Cite

Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.

Journal Article CNS Oncol · September 1, 2021 Purpose: To describe our population of primary brain tumor (PBT) patients, a subgroup of cancer patients whose intensive care unit (ICU) outcomes are understudied. Methods: Retrospective analysis of PBT patients admitted to an ICU between 2013 to 2018 for ... Full text Open Access Link to item Cite

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.

Journal Article Neurooncol Pract · June 2021 BACKGROUND: Spirituality can impact patients' attitudes and decisions about treatment and end-of-life care when coping with cancer. Previous studies documented health-related quality of life (HRQoL) and spiritual well-being (SWB) as positively correlated w ... Full text Link to item Cite

Effect of type and timing of systemic therapy on risk of radiation necrosis in patients with HER2+ breast cancer brain metastases.

Conference Journal of Clinical Oncology · May 20, 2021 e14002 Background: It is estimated that 30% of patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will develop brain metastases. Current standard of care options for HER2+ breast canc ... Full text Cite

Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).

Conference Journal of Clinical Oncology · May 20, 2021 1041 Background: BCBMs are very common in metastatic HER2+ breast cancer. CNS-directed local therapy is the gold standard for treatment, followed by systemic HER2-targeted therapies. In patients with HER2+ BCBM and stable extracr ... Full text Cite

A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.

Journal Article NPJ Vaccines · January 18, 2021 Personalized cancer vaccines targeting neoantigens arising from somatic missense mutations are currently being evaluated for the treatment of various cancers due to their potential to elicit a multivalent, tumor-specific immune response. Several cancers ex ... Full text Open Access Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal Article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.

Journal Article Front Oncol · 2021 OBJECTIVES: Standard 6-week and hypofractionated 3-week courses of adjuvant radiation therapy (RT) are both options for older patients with glioblastoma (GBM), but deciding the optimal regimen can be challenging. This analysis explores clinical factors ass ... Full text Open Access Link to item Cite

Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study.

Journal Article Adv Radiat Oncol · 2021 PURPOSE: To examine the effectiveness and safety of single-isocenter multitarget stereotactic radiosurgery using a volume-adapted dosing strategy in patients with 4 to 10 brain metastases. METHODS AND MATERIALS: Adult patients with 4 to 10 brain metastases ... Full text Link to item Cite

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.

Journal Article Clin Cancer Res · October 15, 2020 Despite standard of care for glioblastoma, including gross total resection, high-dose radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive and therapeutically challenging. The relatively small number of patients with this ... Full text Link to item Cite

ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.

Journal Article Neurosurgery · May 1, 2020 BACKGROUND: An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG). OB ... Full text Link to item Cite

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Journal Article Support Care Cancer · May 2020 PURPOSE: CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has r ... Full text Link to item Cite

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.

Journal Article J Neurooncol · April 2020 PURPOSE: Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin's lymphoma that involves the brain, spinal cord, or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~ 3% of all primary central nervous ... Full text Link to item Cite

Effects of Exercise Therapy Dosing Schedule on Impaired Cardiorespiratory Fitness in Patients With Primary Breast Cancer: A Randomized Controlled Trial.

Journal Article Circulation · February 18, 2020 BACKGROUND: Current exercise guidelines for clinical populations recommend an exercise therapy (ET) prescription of fixed intensity (moderate), duration (40-50 minutes per session), and volume (120-160 min/wk). A critical overarching element of exercise pr ... Full text Link to item Cite

Utilizing a Palliative Care Screening Tool in Patients With Glioblastoma.

Journal Article J Adv Pract Oncol · 2020 Patients with glioblastoma have poor overall survival and experience significant burden from neurologic decline and adverse treatment effects. Despite the well-known benefits of early palliative care integration with oncology care, utilization of palliativ ... Full text Open Access Link to item Cite

Second primary cancers in long-term survivors of glioblastoma.

Journal Article Neurooncol Pract · September 2019 BACKGROUND: Overall survival (OS) in glioblastoma (GBM) is poor at an average of 14 to 18 months, and long-term survivors (LTS) of GBM are rare. LTS of GBM, defined as surviving >5 years postdiagnosis, represent only 2% to 10% of all GBM patients. LTS of c ... Full text Link to item Cite

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

Journal Article Complement Ther Clin Pract · August 2019 BACKGROUND AND PURPOSE: Little is known about complementary and integrative health intervention usage in the primary brain tumor population. We aimed to identify the percentage of patients using these practices and explore the impact on quality of life. MA ... Full text Link to item Cite

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Journal Article Cancer Res · July 1, 2019 Homozygous deletion of methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic alterations in glioblastoma (GBM), but its pathologic consequences remain unclear. In this study, we report that loss of MTAP results in profound epigenetic ... Full text Link to item Cite

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

Conference Journal of Clinical Oncology · May 20, 2019 e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ... Full text Cite

Effects of Non-Linear or Linear Aerobic Training (AT) Dosing Regimens on Impaired Cardiovascular (CV) Function in Patients with Operable Breast Cancer: A Randomized Controlled Trial (RCT).

Conference Journal of Clinical Oncology · May 20, 2019 541 Background: Breast cancer therapy causes marked impairments in CV function predisposing to elevated risk of CV morbidity. We investigated the effects of two AT dosing regimens on CV function in post-treatment patients with op ... Full text Cite

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Conference Journal of Clinical Oncology · May 20, 2019 2060 Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ... Full text Link to item Cite

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Journal Article Health Sci Rep · April 2019 BACKGROUND AND AIMS: This retrospective review of patients with recurrent glioblastoma treated at the Preston Robert Tisch Brain Tumor Center investigated treatment patterns, survival, and safety with bevacizumab in a real-world setting. METHODS: Adult pat ... Full text Link to item Cite

Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Journal Article Nat Med · March 2019 In the version of this article originally published, the figure callout in this sentence was incorrect: "Furthermore, in S1P1-KI mice themselves, whereas PD-1 blockade was ineffectual as monotherapy, the effects of 4-1BB agonism and checkpoint blockade pro ... Full text Link to item Cite

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Journal Article Clin Cancer Res · January 1, 2019 PURPOSE: Chimeric antigen receptor (CAR) T cells have shown promise against solid tumors, but their efficacy has been limited, due in part, to immunosuppression by CD4+FoxP3+ regulatory T cells (Tregs). Although lymphodepletion is commonly used to deplete ... Full text Link to item Cite

MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.

Journal Article J Neuropathol Exp Neurol · January 1, 2019 Glioma therapeutic resistance to alkylating chemotherapy is mediated via O6-methylguanine-DNA methyltransferase (MGMT). We hypothesized that a CD45/HAM56/MGMT double-stained cocktail would improve MGMT discrimination in tumor cells versus inflammatory and ... Full text Link to item Cite

Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.

Journal Article Semin Oncol Nurs · December 2018 OBJECTIVES: To describe the adaptability to the patterns in symptoms and quality of life (QoL) during 6 months post low-grade glioma diagnosis by valid and reliable tools; to identify through qualitative interviews patient/provider adaptive techniques and ... Full text Link to item Cite

Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.

Journal Article J Clin Neurosci · October 2018 Convection Enhanced Delivery (CED) infuses therapeutic agents directly into the intracranial area continuously under pressure. The convection improves the distribution of therapeutics such as those aimed at brain tumors. Although CED successfully delivers ... Full text Link to item Cite

The clinical importance of medulloblastoma extent of resection: a systematic review.

Journal Article J Neurooncol · September 2018 BACKGROUND: Although the majority of current medulloblastoma adjuvant therapy protocols treat patients with ≥ 1.5 cm2 residual tumor as high risk with increased craniospinal irradiation, the true prognostic significance of extent of resection (EOR) in medu ... Full text Link to item Cite

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Journal Article Nat Med · September 2018 T cell dysfunction contributes to tumor immune escape in patients with cancer and is particularly severe amidst glioblastoma (GBM). Among other defects, T cell lymphopenia is characteristic, yet often attributed to treatment. We reveal that even treatment- ... Full text Link to item Cite

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Journal Article Oncologist · August 2018 LESSONS LEARNED: Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall surviva ... Full text Link to item Cite

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Journal Article Clin Cancer Res · August 1, 2018 Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development of a ... Full text Link to item Cite

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Journal Article N Engl J Med · July 12, 2018 BACKGROUND: The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating ... Full text Link to item Cite

Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.

Journal Article Cancer · June 15, 2018 BACKGROUND: The investigation of exercise training in metastatic breast cancer has received minimal attention. This study determined the feasibility and safety of aerobic training in metastatic breast cancer. METHODS: Sixty-five women (age, 21-80 years) wi ... Full text Link to item Cite

Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.

Journal Article Med Sci Sports Exerc · June 2018 PURPOSE: The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. METHODS: Using a retrospective analysis of a randomized trial ... Full text Link to item Cite

Long-term outcomes of adult patients with ependymoma.

Conference Neurology · April 27, 2018 150 ... Link to item Cite

Long-term outcomes of adult patients with ependymoma.

Journal Article Neurology · April 10, 2018 150 ... Link to item Cite

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Journal Article J Neurooncol · April 2018 Prognosis of recurrent glioblastoma (GBM) is poor with 6-month progression-free survival (PFS6) ranging from 9 to 48% depending on the treatment regimen and use of anti-angiogenic therapies. We sought to study vorinostat (VOR), a histone deacetylase inhibi ... Full text Link to item Cite

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.

Journal Article Oncologist · February 2018 LESSONS LEARNED: Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma.Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression-free surviv ... Full text Link to item Cite

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Journal Article Cancer Res · January 1, 2018 Median survival for glioblastoma (GBM) remains <15 months. Human cytomegalovirus (CMV) antigens have been identified in GBM but not normal brain, providing an unparalleled opportunity to subvert CMV antigens as tumor-specific immunotherapy targets. A recen ... Full text Link to item Cite

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Journal Article Oncoimmunology · 2018 Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid tumors clinically. Intracerebral tumors may pose challenges that are even more significant. In orde ... Full text Open Access Link to item Cite

Adjunctive perampanel for glioma-associated epilepsy.

Journal Article Epilepsy Behav Case Rep · 2018 Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy. We conducted ... Full text Link to item Cite

PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Conference Neuro-Oncology · November 1, 2017 RATE-36 INTRODUCTION Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin’s lymphoma that involves the brain, spinal cord or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~3% of all primary centr ... Full text Link to item Cite

Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases

Journal Article Chinese Neurosurgical Journal · October 3, 2017 Background: While the optimal combination of whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) and surgical resection in the treatment of brain metastases, is controversial, the addition of SRS to surgical resction of solitary metastasis may ... Full text Cite

Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Journal Article Neuro Oncol · October 1, 2017 BACKGROUND: Stereotactic radiosurgery (SRS) offers excellent local control for brain metastases (BM) with low rates of toxicity. Radiation necrosis (RN) may occur after treatment and is challenging to distinguish from local recurrence (LR). We evaluated en ... Full text Link to item Cite

A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Journal Article J Neurooncol · September 2017 Primary brain tumor patients experience high levels of distress. The purpose of this cross-sectional, retrospective study is to evaluate the level and different sources of psychosocial distress and how these pertain to health-related quality of life (HRQoL ... Full text Link to item Cite

Rethinking Autoantibody Signature Panels for Cancer Diagnosis.

Journal Article J Thorac Oncol · June 2017 INTRODUCTION: Most pulmonary nodules found on imaging studies are indeterminate, but because of the concern for lung cancer, all patients require further evaluation with resultant radiation risk, significant cost, and delays in diagnosis. We hypothesized t ... Full text Link to item Cite

Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).

Conference Journal of Clinical Oncology · May 20, 2017 e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal c ... Full text Link to item Cite

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.

Conference Journal of Clinical Oncology · May 20, 2017 e13532 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin consisting of EGFR-wt and EGFRvIII monoclonal antibodies with a genetically engineered Pseudomonas exotoxin, PE-38KDEL. The primary objectiv ... Full text Link to item Cite

Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.

Conference Journal of Clinical Oncology · May 20, 2017 e21636 Background: At diagnosis, GBM patients face the immediate challenge of significant morbidity and mortality. In this population, we have shown that better exercise behavior is an independent prognostic factor for improved s ... Full text Link to item Cite

Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.

Conference Neurology · April 27, 2017 Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM. Background: BTSC CD133+ contribute to GBM propagation and are associated with chemo-radiation ... Link to item Cite

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Journal Article Clin Cancer Res · April 15, 2017 Purpose: Patients with glioblastoma have less than 15-month median survival despite surgical resection, high-dose radiation, and chemotherapy with temozolomide. We previously demonstrated that targeting cytomegalovirus pp65 using dendritic cells (DC) can e ... Full text Link to item Cite

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Journal Article Cancer Invest · January 2, 2017 The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who unde ... Full text Link to item Cite

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Journal Article Ther Clin Risk Manag · 2017 PURPOSE: Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority of palonosetron ( ... Full text Link to item Cite

Single fraction stereotactic radiosurgery for multiple brain metastases.

Journal Article Adv Radiat Oncol · 2017 INTRODUCTION: Due to the neurocognitive side effects of whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) is being used with increasing frequency. The use of SRS is expanding for patients with multiple (>4) brain metastases (BM). This s ... Full text Open Access Link to item Cite

Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.

Journal Article CNS Oncol · October 2016 All cancer patients experience distress from the diagnosis, the effects of the disease or the treatment. Clinically significant distress decreases overall quality of life and the recognition of distress with prompt intervention is essential. The National C ... Full text Link to item Cite

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Conference Support Care Cancer · October 2016 BACKGROUND: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially comp ... Full text Link to item Cite

Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.

Journal Article Environ Mol Mutagen · June 2016 Combinations of radiotherapy (RT) and chemotherapy have shown efficacy toward brain tumors. However, therapy-induced oxidative stress can damage normal brain tissue, resulting in both progressive neurocognitive loss and diminished quality of life. We have ... Full text Link to item Cite

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Conference Journal of Clinical Oncology · May 20, 2016 Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion mo ... Full text Link to item Cite

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).

Conference Journal of Clinical Oncology · May 20, 2016 ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with antigens ... Full text Link to item Cite

Baseline cognitive function to predict survival in patients with glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2016 Background: Overall survival of patients with glioblastoma (GBM) remains dismal with range from 12-14 months. In addition to the oncologic burden that these patients face during the disease trajectory, there are demonstrable neurologic and cognitive challe ... Full text Link to item Cite

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.

Journal Article Cancer Immunol Immunother · February 2016 Regulatory B cells that secrete IL-10 (IL-10(+) Bregs) represent a suppressive subset of the B cell compartment with prominent anti-inflammatory capacity, capable of suppressing cellular and humoral responses to cancer and vaccines. B lymphocyte stimulator ... Full text Link to item Cite

Insomnia and its associations in patients with recurrent glial neoplasms.

Journal Article Springerplus · 2016 BACKGROUND: Patient with neurological disorders and cancer can develop sleep disturbance, in particular insomnia. Etiology of insomnia is multi-factorial in primary brain tumour patients with possible causes including corticosteroids, psychoactive medicati ... Full text Open Access Link to item Cite

X-Ray Psoralen Activated Cancer Therapy (X-PACT).

Journal Article PLoS One · 2016 This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative disease and extracorporeal photo ... Full text Open Access Link to item Cite

Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity.

Journal Article J Pain Symptom Manage · October 2015 CONTEXT: Measurement of dyspnea is important for clinical care and research. OBJECTIVES: To characterize the relationship between the 0-10 Numerical Rating Scale (NRS) and four-level categorical Verbal Descriptor Scale (VDS) for dyspnea assessment. METHODS ... Full text Link to item Cite

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

Journal Article Oncologist · July 2015 LESSONS LEARNED: Trials focusing on unresectable multifocal glioblastoma are needed because of the extremely poor prognosis and challenges in receiving standard therapy, such as concurrent radiation and chemotherapy.Developing a strategy to chemically debu ... Full text Link to item Cite

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.

Journal Article J Thorac Oncol · June 2015 INTRODUCTION: Patients with stage I non-small-cell lung cancer (NSCLC) have a wide variation in outcomes, most likely because there are undetected metastases at presentation. We retrospectively reviewed patients with early stage lung cancer to determine if ... Full text Link to item Cite

Secondary cancers in long-term survivors of primary glioblastoma.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 2034 ... Link to item Cite

Prognostic marker analysis in pediatric intracranial ependymomas.

Journal Article J Neurooncol · April 2015 Histologic grading methods dependent upon H&E staining review have not been shown to reliably predict survival in children with intracranial ependymomas due to the subjectivity of the analytical methods. We hypothesized that the immunohistochemical detecti ... Full text Link to item Cite

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.

Journal Article Nature · March 19, 2015 After stimulation, dendritic cells (DCs) mature and migrate to draining lymph nodes to induce immune responses. As such, autologous DCs generated ex vivo have been pulsed with tumour antigens and injected back into patients as immunotherapy. While DC vacci ... Full text Open Access Link to item Cite

Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study.

Journal Article Clin Lymphoma Myeloma Leuk · February 2015 BACKGROUND: The safety and feasibility of the symptom-limited cardiopulmonary exercise test (CPET) and the 6-minute walk test (6MWT) has not been rigorously tested in patients with multiple myeloma (MM) after high-dose chemotherapy with autologous stem cel ... Full text Link to item Cite

Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.

Journal Article Mol Cancer Ther · January 2015 Cranial irradiation is a standard therapy for primary and metastatic brain tumors. A major drawback of radiotherapy (RT), however, is long-term cognitive loss that affects quality of life. Radiation-induced oxidative stress in normal brain tissue is though ... Full text Link to item Cite

Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.

Journal Article Int J Radiat Oncol Biol Phys · January 1, 2015 PURPOSE: To identify an optimal margin about the gross target volume (GTV) for stereotactic radiosurgery (SRS) of brain metastases, minimizing toxicity and local recurrence. METHODS AND MATERIALS: Adult patients with 1 to 3 brain metastases less than 4 cm ... Full text Link to item Cite

Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.

Journal Article J Neurooncol · December 2014 Quality of life (QoL) impairment and fatigue are frequently experienced during treatment for recurrent high-grade glioma (HGG). Fatigue and QoL impairments can be due to primary neurological dysfunction, cytotoxic treatments, mood disturbances, and support ... Full text Link to item Cite

Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study.

Journal Article Bone Marrow Transplant · October 2014 The feasibility of symptom-limited cardiopulmonary exercise testing (CPET) prior to allo-SCT was assessed in addition to the prognostic value of CPET-derived measures. CPET was performed prospectively on 21 patients with hematologic malignancies, with asse ... Full text Link to item Cite

Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients.

Journal Article Oncologist · September 2014 BACKGROUND: The purpose of this study was to investigate the extent of pre-exercise participation ("preparticipation") health screening in a heterogeneous cohort of adult cancer patients. METHODS: Patients (n = 413) with histologically confirmed solid or h ... Full text Link to item Cite

A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.

Journal Article J Neurosurg · September 2014 OBJECT: Robust methodology that allows objective, automated, and observer-independent measurements of brain tumor volume, especially after resection, is lacking. Thus, determination of tumor response and progression in neurooncology is unreliable. The obje ... Full text Link to item Cite

Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.

Journal Article Support Care Cancer · July 2014 PURPOSE: A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting ... Full text Link to item Cite

Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.

Journal Article Neuro Oncol · July 2014 PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tum ... Full text Link to item Cite

Tert promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Journal Article Neuro Oncol · July 2014 Malignant cells must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the telomere binding proteins alpha thalassemia/mental retardation syndrome ... Full text Link to item Cite

Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.

Journal Article Appl Physiol Nutr Metab · June 2014 The purpose of this study was to examine the relationship between self-reported exercise behavior, cardiorespiratory fitness (CRF), and cognitive function in early breast cancer patients. Thirty-seven breast cancer patients following completion of chemothe ... Full text Link to item Cite

Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.

Journal Article Eur Urol · May 2014 UNLABELLED: Erectile dysfunction (ED) is a major adverse effect of radical prostatectomy (RP). We conducted a randomized controlled trial to examine the efficacy of aerobic training (AT) compared with usual care (UC) on ED prevalence in 50 men (n=25 per gr ... Full text Link to item Cite

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Journal Article Oncotarget · March 30, 2014 Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which these two mutations co-occur or o ... Full text Open Access Link to item Cite

EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.

Journal Article Clin Cancer Res · February 15, 2014 PURPOSE: Chimeric antigen receptor (CAR) transduced T cells represent a promising immune therapy that has been shown to successfully treat cancers in mice and humans. However, CARs targeting antigens expressed in both tumors and normal tissues have led to ... Full text Link to item Cite

SEER insights.

Journal Article J Neurosurg · February 2014 Full text Link to item Cite

Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.

Journal Article Breast Cancer Res Treat · February 2014 Conventional resting left ventricular ejection fraction (LVEF) assessments have limitations for detecting doxorubicin (DOX)-related cardiac dysfunction. Novel resting echocardiographic parameters, including 3-dimensional echocardiography (3DE) and global l ... Full text Link to item Cite

Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer.

Journal Article Respirology · January 2014 BACKGROUND AND OBJECTIVE: In this era of increasing options for treatment of 'surgical' lung cancer patients, preoperative physiologic assessment of accurate patient selection is becoming more important. The variability in an objective measure of cardiores ... Full text Link to item Cite

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.

Journal Article PLoS One · 2014 Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor tissue while sparing the normal bra ... Full text Open Access Link to item Cite

Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.

Journal Article Acta Oncol · January 2014 BACKGROUND: To evaluate the safety and efficacy of moderate-to-high intensity aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. METHODS: Twenty patients with stage IIB-IIIC operable breast cancer were randomly assigned to recei ... Full text Link to item Cite

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.

Journal Article J Clin Neurosci · January 2014 Chimeric antigen receptors (CAR)-transduced T cells hold great promise in the treatment of malignant disease. Here, we demonstrate that intracerebral injection with a human, epidermal growth factor receptor variant III (EGFRvIII)-specific, third generation ... Full text Link to item Cite

Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.

Journal Article J Thorac Oncol · December 2013 INTRODUCTION: To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non-small-cell lung cancer (NSCLC). METHODS: One hun ... Full text Link to item Cite

Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Journal Article Cancer Immunol Res · September 2013 A major mechanism by which human regulatory T cells (T(regs)) have been shown to suppress and kill autologous immune cells is through the granzyme-perforin pathway. However, it is unknown whether T(regs) also possess the capacity to kill tumor cells using ... Full text Link to item Cite

Biomarkers to help guide management of patients with pulmonary nodules.

Journal Article Am J Respir Crit Care Med · August 15, 2013 RATIONALE: Indeterminate pulmonary nodules are a common radiographic finding and require further evaluation because of the concern for lung cancer. OBJECTIVES: We developed an algorithm to assign patients to a low- or high-risk category for lung cancer, ba ... Full text Open Access Link to item Cite

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

Journal Article Int J Radiat Oncol Biol Phys · August 1, 2013 PURPOSE: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG. METHODS AND MATERIALS: ... Full text Link to item Cite

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Journal Article J Neurooncol · August 2013 Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized th ... Full text Link to item Cite

BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.

Journal Article Cancer Immunol Immunother · June 2013 B lymphocyte stimulator (BLyS) is a cytokine involved in differentiation and survival of follicular B cells along with humoral response potentiation. Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to e ... Full text Link to item Cite

The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study.

Journal Article Breast Cancer Res Treat · April 2013 We examined cardiorespiratory fitness (CRF) levels in early stage breast cancer patients and determined whether CRF differs as a function of adjuvant therapy regimen. A total of 180 early breast cancer patients representing three treatment groups (surgery ... Full text Link to item Cite

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Journal Article Cancer Med · April 2013 Patients with unresectable glioblastomas have a poor prognosis, with median survival of 6-10 months. We conducted a phase II trial of upfront 5-day temozolomide (TMZ) and bevacizumab (BV) in patients with newly diagnosed unresectable or multifocal glioblas ... Full text Open Access Link to item Cite

Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.

Journal Article Psychooncology · February 2013 OBJECTIVES: This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. METHODS: Sociodemographic data, including ... Full text Open Access Link to item Cite

Subarachnoid hemorrhage trials.

Journal Article J Neurosurg · January 2013 Full text Link to item Cite

Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.

Journal Article PLoS One · 2013 BACKGROUND: While curable at early stages, few treatment options exist for advanced melanoma. Currently, no consensus exists regarding the optimal surveillance strategy for patients after resection. The objectives of this study were to identify patterns of ... Full text Open Access Link to item Cite

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Journal Article PLoS One · 2013 Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, which some suggest may be ... Full text Open Access Link to item Cite

The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.

Journal Article Cancer Invest · November 2012 OBJECTIVES: Metastatic melanoma (MM) is a leading cause of years of life lost due to malignancy. This study aimed to identify the average years of life lost (AYLL) in MM patients. METHODS: MM patients were identified from a prospectively maintained databas ... Full text Link to item Cite

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.

Journal Article Br J Cancer · October 23, 2012 BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among rec ... Full text Open Access Link to item Cite

Clinicopathologic study of 85 cases of melanoma of the female genitalia.

Journal Article J Am Acad Dermatol · October 2012 BACKGROUND: Melanoma of the female genitalia has poor overall prognosis. OBJECTIVE AND METHODS: To examine prognostic factors influencing survival, the Duke Melanoma and Tumor Registry Databases were queried for patients who had received their clinical car ... Full text Link to item Cite

Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients.

Journal Article Support Care Cancer · October 2012 PURPOSE: Spiritual care is an important part of healthcare, especially when facing the crisis of advanced cancer. Do oncology inpatients receive spiritual care consistent with their needs? When inconsistent, are there deleterious effects on patient outcome ... Full text Link to item Cite

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.

Journal Article Cancer · October 1, 2012 BACKGROUND: We evaluated the efficacy of imatinib plus hydroxyurea in patients with progressive/recurrent low-grade glioma. METHODS: A total of 64 patients with recurrent/progressive low-grade glioma were enrolled in this single-center study that stratifie ... Full text Link to item Cite

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.

Journal Article J Neurooncol · August 2012 Intracranial meningiomas are often indolent tumors which typically grow over years to decades. Nonetheless, meningiomas that progress after maximum safe resection and radiation therapy pose a significant therapeutic challenge and effective therapies have y ... Full text Link to item Cite

Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.

Journal Article J Clin Oncol · July 10, 2012 PURPOSE: To evaluate cardiopulmonary function (as measured by peak oxygen consumption [VO(2peak)]) across the breast cancer continuum and its prognostic significance in women with metastatic disease. PATIENTS AND METHODS: Patients with breast cancer repres ... Full text Link to item Cite

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Journal Article J Neurooncol · July 2012 To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma pat ... Full text Link to item Cite

Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.

Journal Article Lung Cancer · May 2012 BACKGROUND: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Using a prospective design, 118 consecutive participants with histologic ... Full text Link to item Cite

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Journal Article J Neurooncol · March 2012 We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] ... Full text Link to item Cite

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.

Journal Article J Neurooncol · March 2012 Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a ... Full text Link to item Cite

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Journal Article Cancer · March 1, 2012 BACKGROUND: The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide. METHODS: There was no limit on the ... Full text Link to item Cite

Clinical data simplified.

Journal Article J Neurosurg · February 2012 Full text Link to item Cite

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

Journal Article Int J Radiat Oncol Biol Phys · January 1, 2012 PURPOSE: To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM). METHODS AND MATERIALS: A total of 125 patients with newly diagnosed GBM were enrolled in ... Full text Link to item Cite

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

Journal Article PLoS One · 2012 BACKGROUND: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy ... Full text Open Access Link to item Cite

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.

Journal Article Nucl Med Biol · January 2012 INTRODUCTION: Malignant glioma remains a significant therapeutic challenge, and immunotherapeutics might be a beneficial approach for these patients. A monoclonal antibody (MAb) specific for multiple molecular targets could expand the treatable patient pop ... Full text Link to item Cite

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Journal Article J Neurooncol · January 2012 We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma. A total of 21 patients with progressive/recurrent meningioma were enrolled in this dual center, single-arm, phase II trial. A ... Full text Link to item Cite

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

Journal Article J Neurooncol · December 2011 We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For ea ... Full text Link to item Cite

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal Article Cancer · December 1, 2011 BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received ca ... Full text Link to item Cite

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.

Journal Article J Neurooncol · December 2011 We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing schedule. The primary objective was to determine the maximum tolerated dose and dose limiting toxicity (DLT) of twice daily SC ... Full text Link to item Cite

The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.

Journal Article J Thorac Oncol · October 2011 INTRODUCTION: Lung cancers can display immune cell infiltration although the role of an adaptive immune response in disease pathogenesis is unknown. To investigate the possibility of a functional humoral response to the tumor, we surveyed histologic sectio ... Full text Link to item Cite

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

Journal Article Blood · September 15, 2011 Lymphodepletion augments adoptive cell transfer during antitumor immunotherapy, producing dramatic clinical responses in patients with malignant melanoma. We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vacc ... Full text Link to item Cite

Epidemiology.

Journal Article J Neurosurg · August 2011 Full text Link to item Cite

Reply to M.S. Lesniak

Journal Article Journal of Clinical Oncology · August 1, 2011 Full text Cite

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

Journal Article J Clin Oncol · July 20, 2011 PURPOSE: Identifying strong markers of prognosis are critical to optimize treatment and survival outcomes in patients with malignant recurrent glioma. We investigated the prognostic significance of exercise behavior and functional capacity in this populati ... Full text Link to item Cite

Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.

Journal Article Int J Cancer · July 1, 2011 Glycoprotein NMB (GPNMB), a transmembrane glycoprotein highly expressed in high-grade gliomas (HGGs), is an attractive target in cancer immunotherapy. We isolated a GPNMB-specific scFv clone, G49, from a human synthetic phage-display library. To obtain mut ... Full text Link to item Cite

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Journal Article Clin Cancer Res · June 15, 2011 PURPOSE: To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective. EXPERIMENTAL DESIGN: A total of 75 patients ... Full text Link to item Cite

Reply to M.C. Chamberlain

Journal Article Journal of Clinical Oncology · June 10, 2011 Full text Cite

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Journal Article J Neurooncol · June 2011 We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received ... Full text Link to item Cite

Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.

Journal Article J Clin Oncol · May 20, 2011 2082 Background: Most patients with a malignant glioma recur after primary chemoradiation. Bevacizumab (BVZ) has been shown in phase II trials to improve disease-free survival in patients with recurrent glioma. Retrospective studies of stereotactic radiosu ... Link to item Cite

Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials.

Journal Article J Clin Oncol · May 20, 2011 2030 Background: Although BV benefits most recurrent GBM patients, the duration of benefit is limited and subsequent survival after BV progression is poor due to lack of effective therapeutic options. METHODS: We performed a meta-analysis of five consecuti ... Link to item Cite

Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.

Journal Article J Clin Oncol · May 20, 2011 2055 Background: Patients with unresectable or multifocal glioblastomas (GBs) have a poor prognosis with median survival of 6-10 months. Given the angiogenic phenotype of GB, we conducted two phase II trials of upfront 5-day temozolomide (TMZ) and Bevacizu ... Link to item Cite

A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).

Journal Article J Clin Oncol · May 20, 2011 2070 Background: AC480 is a novel oral tyrosine kinase inhibitor of the human epidermal growth factor receptor family, especially EGFR and HER2. EGFR is an important therapeutic target in MG. We performed a pilot study to evaluate the tumor and plasma PK o ... Link to item Cite

Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study.

Journal Article Psychooncology · May 2011 OBJECTIVE: In a pilot study, participation in the Pathfinders program was associated with reductions in distress and despair and improvements in quality of life (QOL) among advanced breast cancer patients. This study explores the relationship between psych ... Full text Link to item Cite

Resection of vestibular schwannomas.

Journal Article J Neurosurg · May 2011 Full text Link to item Cite

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

Journal Article J Natl Compr Canc Netw · April 2011 Glioblastoma, the most common primary malignant brain tumor among adults, is a highly angiogenic and deadly tumor. Angiogenesis in glioblastoma, driven by hypoxia-dependent and independent mechanisms, is primarily mediated by vascular endothelial growth fa ... Full text Link to item Cite

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Journal Article Neuro Oncol · March 2011 Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues. Immunotherapeutic targeting of EGFRvIII could eliminate neoplastic c ... Full text Link to item Cite

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.

Journal Article J Neurooncol · January 2011 Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing ... Full text Link to item Cite

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Journal Article Neuro Oncol · December 2010 Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination w ... Full text Link to item Cite

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Journal Article J Clin Oncol · November 1, 2010 PURPOSE: Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed ... Full text Link to item Cite

Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer.

Journal Article Cancer · October 15, 2010 BACKGROUND: Identifying strong markers of prognosis is critical to optimize treatment and survival outcomes in patients with nonsmall cell lung cancer (NSCLC). The authors investigated the prognostic significance of preoperative cardiorespiratory fitness ( ... Full text Link to item Cite

Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer.

Journal Article BMC Cancer · October 6, 2010 BACKGROUND: The Exercise Intensity Trial (EXcITe) is a randomized trial to compare the efficacy of supervised moderate-intensity aerobic training to moderate to high-intensity aerobic training, relative to attention control, on aerobic capacity, physiologi ... Full text Open Access Link to item Cite

Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.

Journal Article Neurol Res · October 2010 OBJECTIVES: While convection enhanced delivery (CED) is an effective delivery method that bypasses the blood-brain barrier, its utility is limited by infusate leakage due to catheter misplacement. Therefore, it is critical to evaluate drug distribution dur ... Full text Link to item Cite

Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.

Journal Article J Pain Symptom Manage · October 2010 CONTEXT: The Patient Care Monitor (PCM) is a review of systems survey delivered by means of an electronic patient-reported outcomes (ePRO) data capture system that uses wireless tablet computers. Although the PCM 1.0 is validated, the updated PCM 2.0 has n ... Full text Link to item Cite

Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial.

Journal Article Lancet · September 4, 2010 BACKGROUND: Palliative oxygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who are ineligible for long-term oxygen therapy. We assessed the effectiveness of oxygen compared with room air delivered by nasal cann ... Full text Link to item Cite

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

Journal Article BMC Cancer · September 1, 2010 BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and validated a promising molecular th ... Full text Open Access Link to item Cite

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Journal Article J Neurosurg · August 2010 OBJECT: Convection-enhanced delivery (CED) is a novel intracerebral drug delivery technique with considerable promise for delivering therapeutic agents throughout the CNS. Despite this promise, Phase III clinical trials employing CED have failed to meet cl ... Full text Link to item Cite

Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.

Journal Article Support Care Cancer · July 2010 PURPOSE: Pathfinders is a multi-faceted psychosocial care program for cancer patients; it was developed in community oncology and adapted to the academic oncology setting. This prospective, single-arm, phase 2 pilot study examined the acceptability and fea ... Full text Link to item Cite

Long-term survival from the initial trial of bevacizumab and irinotecan.

Journal Article JOURNAL OF CLINICAL ONCOLOGY · May 20, 2010 Link to item Cite

Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

Journal Article J Neurooncol · May 2010 A major obstacle in glioblastoma (GBM) therapy is the restrictive nature of the blood-brain barrier (BBB). Convection-enhanced delivery (CED) is a novel method of drug administration which allows direct parenchymal infusion of therapeutics, bypassing the B ... Full text Link to item Cite

Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer.

Journal Article J Appl Physiol (1985) · February 2010 Recent epidemiologic studies report that regular exercise may be associated with substantial reductions in cancer-specific and all-cause mortality following a breast cancer diagnosis. The mechanisms underlying this relationship have not been identified. We ... Full text Link to item Cite

Patterns of Recurrence in Melanoma and the Impact on Survival

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2010 Link to item Cite

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.

Journal Article J Neurooncol · January 2010 Featured Publication We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) ... Full text Link to item Cite

Treatment-related toxicity and supportive care in metastatic colorectal cancer.

Journal Article J Support Oncol · 2010 As survival of metastatic colorectal cancer (mCRC) increases, patients have more exposure to chemotherapy and related toxicity. The objective is to determine how toxicity patterns affect care. Via a population-based strategy, mCRC cases diagnosed between J ... Link to item Cite

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Journal Article Br J Cancer · December 15, 2009 BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 ... Full text Open Access Link to item Cite

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Journal Article J Neurooncol · December 2009 Featured Publication This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM). Prior to radiotherapy, patients were treated with a maximum ... Full text Link to item Cite

Determination of utility scores for control of chemotherapy-induced nausea or vomiting - CALGB 309801

Journal Article Journal of Supportive Oncology · December 1, 2009 Utility scores for temporary health states are not well defined. We investigated two techniques to define utilities for chemotherapy-induced nausea and vomiting. Patients receiving cyclic chemotherapy evaluated various hypothetical health states, each assu ... Cite

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.

Journal Article Mol Cancer Ther · October 2009 Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by nonspecific toxicity. Immunologic targeting of tumor-specific gene mutations, however, may allow more precise ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Journal Article Neuro Oncol · October 2009 This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5-day dosing regimens of temozolomide (TMZ) in combination ... Full text Link to item Cite

Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.

Journal Article J Thorac Oncol · September 2009 BACKGROUND: In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved survival and demonstrated no significant benefit from the addition of induction chemotherapy. The pri ... Full text Link to item Cite

Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.

Journal Article J Oncol Pract · September 2009 Multiple agents and combination therapies available to patients with advanced colorectal cancer have significantly improved survival and provided an opportunity for individualization of care, allowing clinicians and patients to prioritize risks and benefit ... Full text Link to item Cite

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.

Journal Article Cancer · August 1, 2009 Featured Publication BACKGROUND: Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1-year median survival. The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) p ... Full text Link to item Cite

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.

Journal Article Cancer · July 1, 2009 Featured Publication BACKGROUND: The current study was a phase 1 clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG). The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when adminis ... Full text Link to item Cite

Poor documentation prevents adequate assessment of quality metrics in colorectal cancer.

Journal Article J Oncol Pract · July 2009 To standardize oncology clinical practice and improve patient outcomes, multiple organizations have developed cancer-specific metrics on the basis of a systematic background review, expert guidance, and fundamental elements of cancer care-staging and treat ... Full text Link to item Cite

Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.

Journal Article J Pain Symptom Manage · June 2009 Featured Publication Programmed, notebook-style, personal computers ("e/Tablets") can collect symptom and quality-of-life (QOL) data at the point of care. Patients use an e/Tablet in the clinic waiting area to complete electronic surveys. Information then travels wirelessly to ... Full text Link to item Cite

Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.

Journal Article Support Care Cancer · June 2009 Featured Publication GOALS: Management of the risk of potential chemotherapy-induced neutropenic complications such as febrile neutropenia (FN) and severe neutropenia (SN) is a quality of care priority. How frequently does care at our institution conform to established guideli ... Full text Link to item Cite

Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.

Journal Article J Clin Oncol · May 20, 2009 7535 Background: CALGB 39801 was designed to test whether treatment with induction chemotherapy and concurrent chemoradiotherapy (arm B) would improve OS in comparison to identical chemoradiotherapy alone (arm A), and demonstrated no significant benefit in ... Link to item Cite

Impact of a psychosocial intervention on performance status and coping.

Journal Article J Clin Oncol · May 20, 2009 9611 Background: Psychosocial distress is a critical cancer comorbidity; new interventions are needed. Pathfinders, a manualized psychosocial care program, provides patient navigation, counseling, coping skills training, mind/body techniques, and lifestyle ... Link to item Cite

Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM.

Journal Article J Clin Oncol · May 20, 2009 2034 Background: TRegs are increased in patients with GBM and constitutively express the high affinity interleukin-2 receptor (IL-2Rα). Treatment with an antibody that blocks IL-2Rα signaling functionally inactivates and eliminates TRegs without inducing a ... Link to item Cite

Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM.

Journal Article J Clin Oncol · May 20, 2009 2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise eradication of neoplastic cells with reduced toxicity. EGFRvIII is a constitutively activated and immunogenic mutation not express ... Link to item Cite

Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM).

Journal Article J Clin Oncol · May 20, 2009 e13025 Background: GBMs are vascular tumors and inherently resistant to therapy. The prognosis for patients is poor with a median survival of 9-15 months. Patients with unresectable or multifocal GBMs have an even poorer prognosis, with a median survival o ... Link to item Cite

Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL).

Journal Article J Clin Oncol · May 20, 2009 e20703 Background: Cancer survivorship care plans inform and direct care in the survivorship setting. These care plans should be tailored to individual medical information, needs, and circumstances, as providing excess information can be overwhelming. Acco ... Link to item Cite

Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).

Journal Article J Clin Oncol · May 20, 2009 2015 Background: Standard GBM treatment includes TMZ and RT, and results in a median progression-free survival and median survival of 6.9 and 15.8 months, respectively. GBM have high concentrations of vascular endothelial growth factor (VEGF), higher level ... Link to item Cite

Impact of a psychosocial intervention on performance status and coping

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2009 Link to item Cite

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.

Journal Article Cancer · May 15, 2009 Featured Publication BACKGROUND: This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous dail ... Full text Link to item Cite

Reply to A. Katz et al

Journal Article Journal of Clinical Oncology · May 1, 2009 Full text Cite

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Journal Article J Clin Oncol · March 10, 2009 Featured Publication PURPOSE: This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistant malignant glioma and to evaluate the safety of administerin ... Full text Link to item Cite

Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541.

Journal Article Cancer · March 1, 2009 Featured Publication BACKGROUND: The Survivor's Health and Reaction (SHARE) study examined health-related quality of life (HRQL) in breast cancer patients who had participated in Cancer and Leukemia Group B Trial 8541 from 1985 to 1991. METHODS: In total, 245 survivors (78% of ... Full text Link to item Cite

IDH1 and IDH2 mutations in gliomas.

Journal Article N Engl J Med · February 19, 2009 Featured Publication BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that wer ... Full text Link to item Cite

Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804.

Journal Article Psychooncology · February 2009 Featured Publication OBJECTIVE: Improving diet and exercise can reduce survivors' risk of cancer-related fatigue, poor physical functioning, and potential recurrence. A cancer diagnosis can represent a 'teachable moment', leading survivors to make positive changes in diet and ... Full text Link to item Cite

Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804.

Journal Article Cancer · February 1, 2009 Featured Publication BACKGROUND: Little is known about cancer surveillance (mammography, clinical breast examination, and pelvic examination) behaviors in long-term (9-16 years) breast cancer survivors. This report describes the relation of these behaviors to demographic and c ... Full text Link to item Cite

Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.

Journal Article Cancer · February 1, 2009 Featured Publication BACKGROUND: In clinical trials, change in tumor size is used to stratify patients into response categories. The objective of the current study was to: 1) determine whether early change in the tumor size were correlated with survival in patients with advanc ... Full text Link to item Cite

Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Journal Article Clin Cancer Res · February 1, 2009 Featured Publication PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma m ... Full text Link to item Cite

Use of tablet personal computers for sensitive patient-reported information.

Journal Article J Support Oncol · 2009 Featured Publication Notebook-style computers (e/Tablets) are increasingly replacing paper methods for collecting patient-reported information. Discrepancies in data between these methods have been found in oncology for sexuality-related questions. A study was performed to for ... Link to item Cite

Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804.

Journal Article J Cancer Surviv · December 2008 Featured Publication INTRODUCTION: Lymphedema is an under-reported and debilitating consequence of axillary node dissection among breast cancer survivors. This study describes the characteristics of arm and hand swelling in relation to perceived physical and mental health func ... Full text Link to item Cite

Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.

Journal Article Health Serv Res · December 2008 Featured Publication OBJECTIVE: To determine whether e/Tablets (wireless tablet computers used in community oncology clinics to collect review of systems information at point of care) are feasible, acceptable, and valid for collecting research-quality data in academic oncology ... Full text Link to item Cite

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

Journal Article J Immunol Methods · November 30, 2008 Featured Publication The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunothera ... Full text Link to item Cite

Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.

Journal Article BMC Cancer · November 25, 2008 Featured Publication BACKGROUND: Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact ... Full text Open Access Link to item Cite

Comorbidity, age, race and stage at diagnosis in colorectal cancer: A retrospective, parallel analysis of two health systems

Journal Article BMC Cancer · November 25, 2008 Background: Stage at diagnosis plays a significant role in colorectal cancer (CRC) survival. Understanding which factors contribute to a more advanced stage at diagnosis is vital to improving overall survival. Comorbidity, race, and age are known to impact ... Full text Cite

Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.

Journal Article Psychooncology · November 2008 Featured Publication OBJECTIVES: The Survivor's Health and Reaction study used a quality-of-life model adapted for cancer survivors by Dow and colleagues to identify factors related to global health-related quality of life (HRQL) and to document the prevalence of problems and ... Full text Link to item Cite

Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.

Journal Article J Thorac Oncol · November 2008 Featured Publication BACKGROUND: Cancer and Leukemia Group B trial 9430 was a randomized phase II trial which investigated the safety and activity of four novel doublets in untreated extensive stage small cell lung cancer. The results of the paclitaxel and cisplatin arm have n ... Full text Link to item Cite

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Journal Article J Clin Oncol · November 1, 2008 Featured Publication PURPOSE: Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is ef ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Journal Article Clin Cancer Res · November 1, 2008 Featured Publication PURPOSE: Although patients with newly diagnosed WHO grade 3 malignant glioma have a more favorable prognosis than those with WHO grade 4 malignant glioma, salvage therapies following recurrence offer essentially palliative benefit. We did a phase II trial ... Full text Link to item Cite

Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.

Journal Article Lung Cancer · October 2008 Featured Publication PURPOSE: Retrospective data suggests prolonging the time to complete thoracic radiotherapy (TRT) may negatively impact tumor control and survival in limited stage small cell lung cancer (LSCLC). We examined the association between TRT duration and outcomes ... Full text Link to item Cite

Patient education level as a predictor of survival in lung cancer clinical trials.

Journal Article J Clin Oncol · September 1, 2008 Featured Publication PURPOSE: To investigate the effect of socioeconomic status, as measured by education, on the survival of 1,577 lung cancer patients treated on 11 studies conducted by the Cancer and Leukemia Group B. PATIENTS AND METHODS: Sociodemographic data, including e ... Full text Link to item Cite

Quality of life outcomes are equivalent after lobectomy in the elderly.

Journal Article J Thorac Cardiovasc Surg · September 2008 Featured Publication OBJECTIVE: Prospective analyses of quality of life in elderly patients after lobectomy are limited, yet surgeons often recommend suboptimal therapy to these patients on the basis of the belief that lobectomy is poorly tolerated. Surgical decision making in ... Full text Link to item Cite

Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.

Journal Article Dis Colon Rectum · August 2008 Featured Publication PURPOSE: The efficacy of local excision in the treatment of some early-stage distal rectal cancers is still being debated, because few high-quality, long-term prospective data on outcomes are available. METHODS: Fifty-nine patients with T1 lesions were tre ... Full text Link to item Cite

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Journal Article Neuro Oncol · June 2008 Featured Publication The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the epidermal growth factor receptor in patients with recurrent malignant brai ... Full text Link to item Cite

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

Journal Article Neuro Oncol · June 2008 Featured Publication We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bc ... Full text Link to item Cite

E/Tablets to collect research-quality, patient-reported data.

Journal Article J Clin Oncol · May 20, 2008 17528 Background: Programmed, wireless, notebook-and-pen style, computers ("e/Tablets") can collect review of systems data at the point of care, for use in the clinic visit. Can e/Tablets deployed in outpatient oncology clinics be used to collect research ... Link to item Cite

Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC).

Journal Article J Clin Oncol · May 20, 2008 15082 Background: As mCRC survival increases beyond 2 years, patients (pts) have more exposure to multiple CT regimens. Insight into patterns of care in mCRC treatment is crucial to understanding physician and patient decision-making priorities. METHODS: U ... Link to item Cite

Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC).

Journal Article J Clin Oncol · May 20, 2008 15087 Background: As mCRC survival increases, patients have more exposure to chemotherapy (CT) and related toxicity. How do toxicity patterns affect care? METHODS: Using a population-based strategy, we identified CRC cases from 1 academic and 9 community o ... Link to item Cite

Mortality burden of melanoma: Metastatic site-specific and temporal trends.

Journal Article J Clin Oncol · May 20, 2008 9076 Background: Metastatic melanoma has high disease-specific mortality burden, as measured by Years of Life Lost (YLL). Has mortality burden shifted over time? METHODS: This was a retrospective analysis of a prospective database of 14,029 melanoma cases ... Link to item Cite

Mortality burden of melanoma: Metastatic site-specific and temporal trends

Conference Journal of Clinical Oncology · May 20, 2008 Full text Cite

E/Tablets to collect research-quality, patient-reported data

Conference Journal of Clinical Oncology · May 20, 2008 Full text Cite

Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.

Journal Article Neuro Oncol · April 2008 Featured Publication To determine clinical and sociodemographic factors that are associated with major neuropsychiatric illnesses among brain tumor patients, we administered a modified version of the Brief Patient Health Questionnaire and a demographic data form to 363 adult n ... Full text Link to item Cite

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

Journal Article Neuro Oncol · April 2008 Featured Publication The purpose of this study was to determine the feasibility and assess the efficacy and toxicity, among newly diagnosed malignant glioma patients, of administering (131)I-labeled murine antitenascin monoclonal antibody 81C6 ((131)I-81C6) into a surgically c ... Full text Link to item Cite

Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.

Journal Article J Clin Oncol · March 20, 2008 Featured Publication PURPOSE: To determine whether the amount of fluorine-18 fluorodeoxyglucose (FDG) uptake in the primary lung cancer on positron emission tomography (PET) imaging at the time of presentation has prognostic significance in patients with advanced-stage non-sma ... Full text Link to item Cite

Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.

Journal Article Med Care · March 2008 Featured Publication BACKGROUND: Because the elderly are underrepresented on clinical trials, physicians have few sources of information to estimate the risks (ie, toxicities) and benefits of chemotherapy administration to the elderly. OBJECTIVE: Our goal was to determine whet ... Full text Link to item Cite

Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

Journal Article J Thorac Oncol · February 2008 Featured Publication INTRODUCTION: Paclitaxel is an active agent in extensive-stage (ES) small cell lung cancer (SCLC). Nevertheless, the optimal schedule is uncertain. A dose-dense schedule was previously evaluated in a Cancer and Leukemia Group B study of patients with non-S ... Full text Link to item Cite

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Journal Article J Clin Oncol · January 10, 2008 Featured Publication PURPOSE: The combination of a vascular endothelial growth factor (VEGF) -neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas. The ... Full text Link to item Cite

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.

Journal Article Cancer Immunol Immunother · January 2008 Featured Publication PURPOSE: Immunotoxins as anti-cancer therapeutics have several potential advantages over conventional agents including a high specificity, extraordinary potency, and a lack of an identified mechanism for resistance. It has been clearly demonstrated that Ps ... Full text Link to item Cite

Panel of serum biomarkers for the diagnosis of lung cancer.

Journal Article J Clin Oncol · December 10, 2007 Featured Publication PURPOSE: Currently, a blood test for lung cancer does not exist. Serum biomarkers that could aid clinicians in making case management decisions would be enormously valuable. We used two proteomic platforms and a literature search to select candidate serum ... Full text Link to item Cite

Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.

Journal Article Cancer · November 15, 2007 Featured Publication BACKGROUND: The purpose was to evaluate the clinical utility of serum haptoglobin (Hp) and posttranslational glycan modifications of Hp for the diagnosis of nonsmall cell lung cancer (NSCLC). METHODS: Serum proteins from patients with a new diagnosis of NS ... Full text Link to item Cite

Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.

Journal Article J Clin Oncol · November 1, 2007 Featured Publication PURPOSE: To evaluate the technical feasibility and safety of video-assisted thoracic surgery (VATS) lobectomy for small lung cancers. PATIENTS AND METHODS: The Cancer and Leukemia Group B 39802 trial was a prospective, multi-institutional study designed to ... Full text Link to item Cite

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Journal Article J Clin Oncol · October 20, 2007 Featured Publication PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irin ... Full text Link to item Cite

The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.

Journal Article Cancer Res · July 15, 2007 Featured Publication Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of <30%. ARMS is char ... Full text Link to item Cite

Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.

Journal Article J Thorac Oncol · July 2007 Featured Publication INTRODUCTION: A stepwise approach to the functional assessment of lung resection candidates is widely accepted, and this approach incorporates the measurement of exercise peak Vo2 when spirometry and radionuclear studies suggest medical inoperability. A ne ... Full text Link to item Cite

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.

Journal Article Neuro Oncol · July 2007 Featured Publication Convection-enhanced delivery (CED) is a novel drug delivery technique that uses positive infusion pressure to deliver therapeutic agents directly into the interstitial spaces of the brain. Despite the promise of CED, clinical trials have demonstrated that ... Full text Link to item Cite

Comorbidity, age and stage at diagnosis in colorectal cancer (CRC)

Conference JOURNAL OF CLINICAL ONCOLOGY · June 20, 2007 Link to item Cite

Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.

Journal Article J Thorac Oncol · June 2007 Featured Publication INTRODUCTION: Positron emission tomography (PET) has improved the accuracy of staging non-small cell lung cancer (NSCLC), although some early-stage patients will still relapse. The purpose of this study was to determine the sites and time to recurrence in ... Full text Link to item Cite

A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

Journal Article J Thorac Oncol · June 2007 Featured Publication INTRODUCTION: The impact of chemotherapy dose delivery has not been well studied in patients with non-small cell lung cancer (NSCLC). Overlapping hematologic toxicities commonly limit planned dose intensity of combination chemotherapy regimens. A phase II ... Full text Link to item Cite

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Journal Article J Clin Oncol · May 1, 2007 Featured Publication PURPOSE: Standard therapy for unresectable stage III non-small-cell lung cancer includes concomitant chemoradiotherapy. In Cancer and Leukemia Group B 39801, we evaluated whether induction chemotherapy before concurrent chemoradiotherapy would result in im ... Full text Link to item Cite

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

Journal Article Nucl Med Biol · May 2007 Featured Publication INTRODUCTION: The neurohistological findings in patients treated with targeted beta emitters such as (131)I are poorly described. We report a histopathologic analysis from patients treated with combined external beam therapy and a brachytherapy consisting ... Full text Link to item Cite

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Journal Article J Neurooncol · May 2007 Featured Publication PURPOSE: Recent reports demonstrate the activity of imatinib mesylate, an ATP-mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme. We performed the current phase 2 s ... Full text Link to item Cite

In reply [8]

Journal Article Journal of Clinical Oncology · April 10, 2007 Full text Cite

Temozolomide in children with progressive low-grade glioma.

Journal Article Neuro Oncol · April 2007 Featured Publication We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4-18 years). Eligible patient ... Full text Link to item Cite

In reply [14]

Journal Article Journal of Clinical Oncology · March 20, 2007 Full text Cite

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Journal Article Clin Cancer Res · February 15, 2007 Featured Publication PURPOSE: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizuma ... Full text Link to item Cite

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

Journal Article Ann Oncol · February 2007 Featured Publication BACKGROUND: This phase II study evaluated the efficacy and safety of the irinotecan/gemcitabine combination in patients with relapsed/refractory small-cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with measurable tumor who had received one previo ... Full text Link to item Cite

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

Journal Article Neuro Oncol · January 2007 Featured Publication Cloretazine (VNP40101M) is a newly synthesized alkylating agent belonging to a novel class of alkylating agents called 1,2-bis(sulfonyl)hydrazines. Agents that belong to this class do not produce vinylating and chloroethylating species, and hence this clas ... Full text Link to item Cite

Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.

Journal Article Cancer · December 1, 2006 Featured Publication BACKGROUND: Significant barriers to cancer patients receiving mental health treatment for distress have been reported in the literature. The objective of the current study was to determine whether distress in older patients (aged 65 years and older) would ... Full text Link to item Cite

Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.

Journal Article J Surg Oncol · December 1, 2006 Featured Publication BACKGROUND AND OBJECTIVES: CALGB 8935 was a phase II protocol for mediastinoscopically staged IIIA (N2) non-small cell lung cancer. Induction cisplatin/vinblastine chemotherapy was followed by surgical resection, adjuvant cisplatin/vinblastine, and radioth ... Full text Link to item Cite

2498

Conference International Journal of Radiation Oncology*Biology*Physics · November 2006 Full text Cite

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.

Journal Article Br J Cancer · October 23, 2006 Featured Publication Elevated intratumoral interstitial fluid pressure (IFP) and tumour hypoxia are independent predictive factors for poor survival and poor treatment response in cancer patients. However, the relationship between IFP and tumour hypoxia has not yet been clearl ... Full text Open Access Link to item Cite

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.

Journal Article Mol Cancer Ther · October 2006 Featured Publication Promoter hypermethylation of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT) has been associated with an enhanced response to chloroethylating and methylating agents in patients with malignant glioma. The purpose of this study was to co ... Full text Link to item Cite

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

Journal Article Int J Radiat Oncol Biol Phys · October 1, 2006 Featured Publication PURPOSE: Thalidomide has broad anticytokine properties, which might protect normal tissues in patients undergoing chemoradiotherapy. The purpose of this study was to determine the maximal tolerated dose of thalidomide when used in combination with vinorelb ... Full text Link to item Cite

Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).

Journal Article J Natl Cancer Inst · September 20, 2006 Featured Publication To determine the accuracy with which Medicare claims data measure disease-free survival in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We merged gold-standard clinical trial data of 45 elderly patients with node-p ... Full text Open Access Link to item Cite

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Journal Article J Clin Oncol · September 1, 2006 Featured Publication PURPOSE: To determine in a randomized prospective multi-institutional trial whether the addition of tumor necrosis factor alpha (TNF-alpha) to a melphalan-based hyperthermic isolated limb perfusion (HILP) treatment would improve the complete response rate ... Full text Link to item Cite

Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas.

Journal Article J Clin Oncol · June 20, 2006 1506 Background: The prognosis for recurrent malignant gliomas is poor, with a median survival <12 months, median progression-free survival <12 weeks and response rates <20%. Malignant gliomas have high concentrations of VEGF receptors, and the higher the ... Link to item Cite

Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.

Journal Article J Clin Oncol · June 20, 2006 7007 Background: In 2004, preliminary results of CALGB 9633 demonstrated statistically significant evidence that adjuvant chemotherapy with paclitaxel and carboplatin (PC) improved disease-free (DFS) and overall survival (OS) in resected stage IB NSCLC. In ... Link to item Cite

Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.

Journal Article Ann Thorac Surg · June 2006 Featured Publication BACKGROUND: Patients with early stage nonsmall-cell lung cancer who have undergone complete resection have a recurrence rate of approximately 50%, predominately due to the development of systemic metastases. This study is a prospective analysis of the expr ... Full text Link to item Cite

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

Journal Article J Nucl Med · June 2006 Featured Publication UNLABELLED: Results from animal experiments have shown that human IgG2/mouse chimeric antitenascin 81C6 (ch81C6) monoclonal antibody exhibited higher tumor accumulation and enhanced stability compared with its murine parent. Our objective was to determine ... Link to item Cite

Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.

Journal Article Clin Cancer Res · April 1, 2006 Featured Publication PURPOSE: More brain tumor markers are required for prognosis and targeted therapy. We have identified and validated promising molecular therapeutic glioblastoma multiforme (GBM) targets: human transmembrane glycoprotein nonmetastatic melanoma protein B (GP ... Full text Link to item Cite

Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Journal Article Ann Surg Oncol · April 2006 Featured Publication BACKGROUND: American College of Surgeons Oncology Group Z0010 is a prospective multicenter trial designed to evaluate the prognostic significance of micrometastases in the sentinel lymph nodes and bone marrow aspirates of women with early-stage breast canc ... Full text Link to item Cite

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).

Journal Article J Clin Oncol · March 20, 2006 Featured Publication PURPOSE: Hepatic metastases derive most of their blood supply from the hepatic artery; therefore, for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome. METHODS: In a multi-institut ... Full text Link to item Cite

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Journal Article Cancer Res · March 15, 2006 Featured Publication Immunosuppression is frequently associated with malignancy and is particularly severe in patients with malignant glioma. Anergy and counterproductive shifts toward T(H)2 cytokine production are long-recognized T-cell defects in these patients whose etiolog ... Full text Link to item Cite

Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.

Journal Article Ann Thorac Surg · March 2006 Featured Publication BACKGROUND: Little prospective, multiinstitutional data exist regarding the morbidity and mortality after major pulmonary resections for lung cancer or whether a mediastinal lymph node dissection increases morbidity and mortality. METHODS: Prospectively co ... Full text Link to item Cite

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Journal Article Clin Cancer Res · February 1, 2006 Featured Publication PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among pat ... Full text Link to item Cite

Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

Journal Article J Clin Oncol · January 20, 2006 Featured Publication PURPOSE: Among patients with small-cell lung carcinoma, African Americans have lower survival rates than non-African Americans. We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/ ... Full text Link to item Cite

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Journal Article Clin Drug Investig · 2006 Featured Publication OBJECTIVE: To determine the feasibility and maximum tolerated dose of dose-dense topotecan as induction chemotherapy before standard therapy (carboplatin plus etoposide alone or in combination with radiotherapy) in patients with small cell lung cancer (SCL ... Full text Link to item Cite

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

Journal Article J Clin Oncol · January 1, 2006 Featured Publication PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients. PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I ... Full text Link to item Cite

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Journal Article J Clin Oncol · December 20, 2005 Featured Publication PURPOSE: We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiform ... Full text Link to item Cite

In reply [4]

Journal Article Journal of Clinical Oncology · December 1, 2005 Full text Cite

In reply [12]

Journal Article Journal of Clinical Oncology · December 1, 2005 Full text Cite

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.

Journal Article Cancer · October 15, 2005 Featured Publication BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high-dose chemotherapy with autologo ... Full text Link to item Cite

Survival analysis of presumptive prognostic markers among oligodendrogliomas.

Journal Article Cancer · October 15, 2005 Featured Publication BACKGROUND: Allelic losses of 1p and 19q arms correlate with the oligodendroglial phenotype as well as with sensitivity to radiotherapy and chemotherapy. Furthermore, the DNA repair gene, methylguanine methyltransferase (MGMT), is diminished in 80% of olig ... Full text Link to item Cite

Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.

Journal Article Ann Surg · October 2005 Featured Publication OBJECTIVE: Marked variations in sentinel lymph node dissection (SLND) technique have been identified, and definitive qualifications for SLND performance remain controversial. Based on previous reports and expert opinion, we predicted that 20 to 30 cases of ... Full text Link to item Cite

Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.

Journal Article Am J Surg · October 2005 Featured Publication BACKGROUND: Historically, fewer than 5% of cancer patients enroll in clinical trials and lack of physician participation is a contributing factor. In 1999, the American College of Surgeons Oncology Group (ACOSOG) conducted a multicenter breast cancer trial ... Full text Link to item Cite

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

Journal Article Cancer · October 1, 2005 Featured Publication BACKGROUND: The authors determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan (CPT-11), a topoisomerase I inhibitor, when administered with temozolomide among patients with recurrent malignant glioma (MG). METHODS: Pati ... Full text Link to item Cite

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal Article J Clin Oncol · October 1, 2005 Featured Publication PURPOSE: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The ... Full text Link to item Cite

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

Journal Article J Natl Cancer Inst · July 20, 2005 Featured Publication To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treat ... Full text Link to item Cite

Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.

Journal Article Clin Lung Cancer · July 2005 Featured Publication BACKGROUND: This phase II cooperative group study of patients with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with th ... Full text Link to item Cite

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

Journal Article J Clin Oncol · June 1, 2005 Featured Publication PURPOSE: To determine, in a randomized comparison, whether the addition of paclitaxel to etoposide and cisplatin improves the time to progression and overall survival in patients with extensive small-cell lung cancer (SCLC) compared with standard etoposide ... Full text Link to item Cite

Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

Journal Article Lung Cancer · June 2005 Featured Publication PURPOSE: This Phase II trial was designed to determine the response rate, survival, failure-free survival, and toxicity of second-line therapy with karenitecin in patients with relapsed or refractory non-small cell lung cancer (NSCLC). METHODS: Eligibility ... Full text Link to item Cite

Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.

Journal Article Lung Cancer · June 2005 Featured Publication PURPOSE: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the activity of irinotecan in malignant mesothelioma (CALGB protocol 9733). PATIENTS AND METHODS: Twenty-eight patients accrued between January 1998 and Ja ... Full text Link to item Cite

Economic outcomes of breast cancer survivorship: CALGB study 79804.

Journal Article Breast Cancer Res Treat · May 2005 Featured Publication BACKGROUND: Over 80% of women diagnosed with breast cancer will be survivors. We sought to determine the economic consequences of surviving breast cancer. METHODS: Disease-free survivors who had received adjuvant chemotherapy for stage II breast cancer on ... Full text Link to item Cite

Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.

Journal Article Lung Cancer · May 2005 Featured Publication PURPOSE: A major problem with the staging system for non-small cell lung cancer (NSCLC) is clinical underestimation of the extent of disease. Many patients with clinical stage 1 disease do not retain that designation following surgical resection. Herein, w ... Full text Link to item Cite

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

Journal Article Cancer · April 15, 2005 Featured Publication BACKGROUND: The overexpression of HER-2 occurs in a minority of patients with nonsmall cell lung carcinoma. Trastuzumab, which is a monoclonal antibody to HER-2, is an effective treatment in some women with breast carcinomas that overexpress HER-2, as demo ... Full text Link to item Cite

Safety and efficacy of weekly oral oltipraz in chronic smokers.

Journal Article Cancer Epidemiol Biomarkers Prev · April 2005 Featured Publication Cigarette smoking is thought to contribute to carcinogenesis by formation of DNA adducts of tobacco smoke constituents leading to genotoxic damage. The dithiolethione, oltipraz, is a putative cancer chemopreventive agent that induces phase II detoxifying e ... Full text Link to item Cite

Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.

Journal Article J Thorac Cardiovasc Surg · April 2005 Featured Publication OBJECTIVES: This study examined the feasibility of thoracoscopic wedge resection and radiotherapy for clinical T1 lesions in patients with compromised cardiopulmonary status. METHODS: In this phase II, prospective, multicenter, cooperative group trial, hig ... Full text Link to item Cite

Pulmonary vein diameter, cross-sectional area, and shape: CT analysis.

Journal Article Radiology · April 2005 Featured Publication PURPOSE: To retrospectively establish normal values for pulmonary vein diameter, cross-sectional area, and shape depicted at computed tomography (CT). MATERIALS AND METHODS: Institutional review board waived patient consent requirement and approved the stu ... Full text Link to item Cite

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Journal Article Clin Cancer Res · March 15, 2005 Featured Publication PURPOSE: The Cancer and Leukemia Group B conducted a phase II study of gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously untreated malignant mesothelioma. EXPERIMENTAL DESIGN: Eligible patie ... Full text Link to item Cite

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Journal Article Clin Cancer Res · March 15, 2005 Featured Publication PURPOSE: To assess the relationship between molecular markers associated with chemotherapy resistance and survival in esophageal cancer patients treated with trimodality therapy. EXPERIMENTAL DESIGN: The original pretreatment formalin-fixed, paraffin-embed ... Full text Link to item Cite

Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Journal Article Chest · March 2005 Featured Publication STUDY OBJECTIVE: To demonstrate the efficacy, safety, and appropriate mode of instillation of talc for sclerosis in treatment of malignant pleural effusions (MPEs). DESIGN: A prospective, randomized trial was designed to compare thoracoscopy with talc insu ... Full text Link to item Cite

A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).

Journal Article Am J Clin Oncol · February 2005 Featured Publication Based on both clinical and laboratory data that suggested that tamoxifen (TAM) enhanced the effectiveness of cisplatin (DDP)-based chemotherapy regimens, the Cancer and Leukemia Group B (CALGB) designed and initiated a prospective, randomized phase III tri ... Full text Link to item Cite

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.

Journal Article Cancer · January 15, 2005 Featured Publication BACKGROUND: In the current study, the authors report a Phase II trial of irinotecan (CPT-11), a topoisomerase I inhibitor active against malignant glioma (MG), with celecoxib, a selective COX-2 inhibitor, among MG patients with recurrent disease. METHODS: ... Full text Link to item Cite

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

Journal Article J Clin Oncol · January 1, 2005 Featured Publication PURPOSE: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in ... Full text Link to item Cite

[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.

Journal Article Neurosurgery · December 2004 Featured Publication OBJECTIVE: We evaluated the [(18)F]fluorodeoxyglucose (FDG) accumulation during positron emission tomography (PET) in patients with medulloblastoma and examined the relationship of intensity of uptake with patient outcome after the initial scan. METHODS: M ... Full text Link to item Cite

Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.

Journal Article Lung Cancer · December 2004 Featured Publication Biomarkers have the potential to significantly change diagnostic strategies and influence therapeutic management. We developed a MALDI-TOF protein expression profiling platform for biomarker discovery and a proof-of-principle study identified two proteins, ... Full text Link to item Cite

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

Journal Article Cancer · November 15, 2004 Featured Publication BACKGROUND: Research has suggested that men with hormone-refractory prostate carcinoma have a lower quality of life (QOL) compared with men who have hormone-sensitive prostate carcinoma and that quality of life (QOL) steadily declines over the last year of ... Full text Link to item Cite

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Journal Article J Clin Oncol · November 1, 2004 Featured Publication PURPOSE: To prospectively determine the maximum-tolerated dose of accelerated hyperfractionated conformal radiotherapy (RT; 1.6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carbop ... Full text Link to item Cite

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.

Journal Article Lung Cancer · September 2004 Featured Publication PURPOSE: To assess the efficacy and toxicity of 6-hydroxymethylacylfulvene (HMAF; MGI-114, irofulven) as therapy for relapsed or refractory non-small cell lung cancer. METHODS: A two-stage phase II design was employed separately for refractory and relapsed ... Full text Link to item Cite

Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Journal Article J Mol Diagn · August 2004 Featured Publication Astrocytoma is comprised of a group of common intracranial neoplasms that are classified into four grades based on the World Health Organization histological criteria and patient survival. To date, histological grade, patient age, and clinical performance, ... Full text Link to item Cite

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.

Journal Article J Clin Oncol · July 15, 2004 7005 Background: Standard therapy for unresectable stage III NSCLC includes concomitant chemoradiotherapy. In CALGB 39801, we evaluated whether the addition of induction chemotherapy prior to CT/XRT would result in improved survival. METHODS: Between 10/19 ... Link to item Cite

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

Journal Article Ann Oncol · July 2004 Featured Publication BACKGROUND: Combined modality therapy (CMT) is the standard of care for patients with unresectable stage III non-small-cell lung cancer (NSCLC); however, insufficient data are available regarding prognostic factors in this disease setting. PATIENTS AND MET ... Full text Link to item Cite

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

Journal Article Int J Radiat Oncol Biol Phys · June 1, 2004 Featured Publication PURPOSE: To prospectively evaluate the feasibility of delivering 70 Gy once-daily thoracic radiotherapy (TRT), concurrent with chemotherapy, in the treatment of limited-stage small-cell lung cancer (L-SCLC). MATERIALS AND METHODS: Eligible patients receive ... Full text Link to item Cite

Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.

Journal Article Lung Cancer · June 2004 Featured Publication The purpose of this study was to compare the accuracy and agreement of whole-body positron-emission tomography (PET) scan to bone scintigraphy for the detection of bony metastases in staging patients with newly diagnosed lung cancer. The tumor registry and ... Full text Link to item Cite

Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.

Journal Article J Clin Oncol · June 1, 2004 Featured Publication PURPOSE: Low-dose computed tomography (CT) has been suggested for lung cancer screening. Several observational trials have published their preliminary results, and some investigators suggest that this technique will save lives. There are no mortality stati ... Full text Link to item Cite

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

Journal Article Lung Cancer · May 2004 Featured Publication PURPOSE: The CALGB performed a phase II multicenter study to evaluate the activity of oral capecitabine in patients with malignant mesothelioma (CALGB 39807). PATIENTS AND METHODS: Between November 15, 2000 and August 31, 2001, 27 patients with mesotheliom ... Full text Link to item Cite

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

Journal Article Neuro Oncol · April 2004 Featured Publication Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, for patients with recurrent or prog ... Full text Link to item Cite

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Journal Article Neuro Oncol · April 2004 Featured Publication In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG). We previously established the maximum tolerated dose of CPT-11 when administere ... Full text Link to item Cite

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

Journal Article Ann Oncol · March 2004 Featured Publication BACKGROUND: To evaluate the activity and tolerability of gemcitabine plus irinotecan or docetaxel as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Eligible patients with chemotherapy-naïve stage IIIB or IV N ... Full text Link to item Cite

Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation.

Journal Article Radiology · March 2004 Featured Publication PURPOSE: To evaluate and classify the various drainage patterns of the pulmonary veins as depicted with thin-section chest computed tomography (CT). MATERIALS AND METHODS: Thin-section (2.5-mm collimation) contrast material-enhanced CT scans of 201 consecu ... Full text Link to item Cite

Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.

Journal Article Am J Clin Oncol · February 2004 Featured Publication Small-cell lung cancer that progresses after initial response may still be sensitive to systemic treatment. This study assessed doxorubicin plus vinorelbine tartrate (Navelbine Injection) in patients who had no prior exposure to these agents. Treatment con ... Full text Link to item Cite

Phase II trial of gefitinib in recurrent glioblastoma.

Journal Article J Clin Oncol · January 1, 2004 Featured Publication PURPOSE: To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. PATIENTS AND METHODS: This was an op ... Full text Link to item Cite

Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761.

Journal Article Clin Cancer Res · November 15, 2003 Featured Publication PURPOSE: Our purpose was to study the detection of occult metastases (OM) in regional lymph nodes using immunohistochemical stain for cytokeratin, and for this study we targeted clinical stage I patients with non-small cell lung cancer. EXPERIMENTAL DESIGN ... Link to item Cite

Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.

Journal Article J Mol Diagn · November 2003 Featured Publication Positive control materials for clinical molecular genetic testing applications are currently in critically short supply or non-existent for many genetically based diseases of public health importance. Here we demonstrate that anonymous, residual, clinical ... Full text Link to item Cite

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Journal Article J Neurooncol · October 2003 Featured Publication TP-38 is a recombinant chimeric targeted toxin composed of the EGFR binding ligand TGF-alpha and a genetically engineered form of the Pseudomonas exotoxin, PE-38. After in vitro and in vivo animal studies that showed specific activity and defined the maxim ... Full text Link to item Cite

Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.

Journal Article Cancer · August 15, 2003 Featured Publication BACKGROUND: The long-term impact of breast carcinoma and its treatment was assessed in 153 breast carcinoma survivors previously treated on a Phase III randomized trial (Cancer and Leukemia Group B [CALGB 7581]) a median of 20 years after entry to CALGB 75 ... Full text Link to item Cite

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

Journal Article Int J Radiat Oncol Biol Phys · July 15, 2003 Featured Publication PURPOSE: To report the incidence of late complications in long-term survivors of very-high-dose thoracic radiotherapy (RT) treated on a prospective clinical trial. METHODS AND MATERIALS: Patients with locally advanced or medically inoperable non-small-cell ... Full text Link to item Cite

Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage.

Journal Article Radiology · July 2003 Featured Publication PURPOSE: To assess the efficacy of treating pleural effusions in lung transplant recipients with small-bore catheter drainage. MATERIALS AND METHODS: Chest radiographs and computed tomographic (CT) scans obtained in 31 lung transplant recipients who had pl ... Full text Link to item Cite

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.

Journal Article Ann Thorac Surg · July 2003 Featured Publication BACKGROUND: The long-term survival of patients with stage III non-small cell lung cancer treated with a combination of chemotherapy and radiation is 10% to 20%. Survival could potentially be increased and toxicity limited if one could identify patients mos ... Full text Link to item Cite

High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.

Journal Article J Clin Oncol · June 1, 2003 Featured Publication PURPOSE: We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL). PATIENTS AND METHODS: Twelve patients with PBL were initial ... Full text Link to item Cite

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

Journal Article Cancer · May 15, 2003 Featured Publication BACKGROUND: The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy-naïve, advanced-stage non-small cell lung ca ... Full text Link to item Cite

Sub-classification of glioblastoma defined by comparative genomic hybridization alterations.

Conference JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY · May 1, 2003 Link to item Cite

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Journal Article J Clin Oncol · February 15, 2003 Featured Publication PURPOSE: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3-methyltriazen-1yl)imidazole-4-carboximide under physiologic conditions. Previous studi ... Full text Link to item Cite

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

Journal Article J Clin Oncol · October 15, 2002 Featured Publication PURPOSE: To evaluate new drugs in combination with cisplatin in unresectable stage III non-small-cell lung cancer, Cancer and Leukemia Group B (CALGB) conducted a randomized phase II study of two cycles of induction chemotherapy followed by two additional ... Full text Link to item Cite

Randomized controlled clinical trial of weekly oltipraz in smokers.

Conference CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION · October 1, 2002 Link to item Cite

Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer.

Journal Article Clin Lung Cancer · September 2002 Featured Publication Preoperative chemotherapy in patients with stage III non-small-cell lung cancer (NSCLC) remains controversial. Phase II trials utilizing preoperative chemotherapy in selected patients have achieved complete resection rates of 50%-70% with 3-5 year failure- ... Full text Link to item Cite

Phase II study of carboplatin in children with progressive low-grade gliomas.

Journal Article J Clin Oncol · July 1, 2002 Featured Publication PURPOSE: To assess the rate of tumor response and activity of carboplatin in stabilizing the growth of progressive low-grade gliomas. PATIENTS AND METHODS: Eligible patients received carboplatin 560 mg/m(2) intravenously every 4 weeks for 1 year after maxi ... Full text Link to item Cite

Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.

Journal Article AJR Am J Roentgenol · July 2002 Featured Publication OBJECTIVE: The purpose of our study was to assess the usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions and to assess the affect of ascites on the su ... Full text Link to item Cite

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.

Journal Article J Clin Oncol · May 15, 2002 Featured Publication PURPOSE: The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221). PATIENTS AND METHODS: One hundred ninety-one patients (mean age, 67.5 year ... Full text Link to item Cite

Molecular markers of prognosis in astrocytic tumors.

Journal Article Cancer · May 15, 2002 Featured Publication BACKGROUND: Astrocytoma is a primary brain tumor that affects 20,000 Americans each year. To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective s ... Full text Link to item Cite

T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.

Journal Article Radiology · May 2002 Featured Publication PURPOSE: To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission tomography (PET) in patients with T1 (< or =3 cm) lung cancers. MATERIALS AND METHODS: One hundred eighty-five patients with 192 histopathologically proved T1 lung cancers ... Full text Link to item Cite

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

Journal Article J Clin Oncol · May 1, 2002 Featured Publication PURPOSE: We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent ... Full text Link to item Cite

The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033.

Journal Article Qual Life Res · May 2002 Featured Publication The purposes of this study were 2-fold: to evaluate the impact of the schedule dependency of etoposide (3-day IV short course vs. a 21-day oral prolonged course) with cisplatin on the quality of life of small-cell lung cancer (SCLC) patients; and to examin ... Full text Link to item Cite

Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.

Journal Article J Thorac Cardiovasc Surg · March 2002 Featured Publication OBJECTIVE: The 5-year survival for patients with surgically resected stage I non-small cell lung cancer is only 60% to 70%, probably because of undetected systemic occult micrometastases. Detection of occult micrometastases in lymph nodes by reverse-transc ... Full text Link to item Cite

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Journal Article J Clin Oncol · March 1, 2002 Featured Publication PURPOSE: To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma. PATIENTS AND METHODS: In this phase ... Full text Link to item Cite

Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

Journal Article J Natl Cancer Inst · February 20, 2002 Featured Publication BACKGROUND: Among patients diagnosed with advanced non-small-cell lung carcinoma (NSCLC), African-Americans have lower survival rates than non-African-Americans. Whether this difference is due to innate characteristics of the disease in the two ethnicities ... Full text Link to item Cite

Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

Journal Article Clin Lung Cancer · February 2002 Featured Publication Chemotherapy for extensive-stage small-cell lung cancer (E-SCLC) produces high response rates and improved survival but few cures. We tested three new regimens for E-SCLC that might merit further investigation in a subsequent phase III trial. Cancer and Le ... Full text Link to item Cite

Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.

Journal Article Cancer Invest · 2002 Featured Publication Cisplatin based chemotherapies have increased the survival in nonsmall cell lung cancer. A mechanism for identifying tumors resistant to cisplatin would be useful in avoiding unnecessary toxicity of platinum regimens. Mutation of p53 has been shown to indu ... Full text Link to item Cite

Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.

Journal Article Cancer · January 1, 2002 Featured Publication BACKGROUND: Despite a greater risk of malignancy and a higher cancer mortality rate for patients age > 65 years, bias in accruing older patients to clinical trials persists. The results from two National Cancer Institute-approved cooperative group trials ( ... Full text Link to item Cite

Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening.

Journal Article Cancer · December 15, 2001 Featured Publication BACKGROUND: Recently, there has been increased interest in the use of computed tomography (CT) for lung carcinoma screening. For this technique to be effective, small tumors must be detected at an earlier stage than large lesions. However, to the authors's ... Full text Link to item Cite

Stage distribution in patients with a small (

Journal Article Cancer · December 2001 BACKGROUND: Recently, there has been increased interest in the use of computed tomography (CT) for lung carcinoma screening. For this technique to be effective, small tumors must be detected at an earlier stage than large lesions. However, to the authors's ... Cite

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.

Journal Article Lung Cancer · November 2001 Featured Publication Doxorubicin is the most widely studied agent for the treatment of malignant mesothelioma. In conventional doses, the response rate is approximately 17%. Higher dose doxorubicin has been successfully employed in other tumor types. Dexrazoxane has been demon ... Full text Link to item Cite

Predicting the sites of metastases from lung cancer using molecular biologic markers.

Journal Article Ann Thorac Surg · October 2001 Featured Publication BACKGROUND: The use of molecular markers in staging non-small cell lung cancer (NSCLC) has been supported in retrospective prognostic models but has not been evaluated in predicting sites of metastases. METHODS: Pathologic specimens were collected from 202 ... Full text Link to item Cite

Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.

Journal Article Neuro Oncol · October 2001 Featured Publication Both Gliadel wafers [1,3-bis(2-chloroethyl)-1-nitrosourea] and temozolomide (TEMO) have been shown in independent studies to prolong survival of patients with recurrent malignant glioma following surgery and radiotherapy. On the basis of preclinical eviden ... Full text Link to item Cite

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

Journal Article J Clin Oncol · September 1, 2001 Featured Publication PURPOSE: The ability to prescribe treatment based on relative risks for normal tissue injury has important implications for oncologists. In non-small-cell lung cancer, increasing the dose of radiation may improve local control and survival. Changes in plas ... Full text Link to item Cite

Tumor marker expression is predictive of survival in patients with esophageal cancer.

Journal Article Ann Thorac Surg · September 2001 Featured Publication BACKGROUND: This study was designed to determine the prognostic value of immunohistochemical tumor marker expression in a population of patients with node-negative esophageal cancer treated with complete resection alone. METHODS: Resection specimens were c ... Full text Link to item Cite

Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer

Journal Article Anticancer Research · June 11, 2001 Background: CA 125 and CEA are valuable serum tumor markers that can be used to monitor response to therapy in patients with various solid tumors. Systemic studies of CA 125 and CEA have not been evaluated in lung cancer. In this study, we report the serum ... Cite

The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.

Journal Article Ann Oncol · May 2001 Featured Publication OBJECTIVES: The quality of life (QoL) of 44 men with HRPC and 37 partners (primary caregivers, most residing with the patient) was assessed in a multicenter Phase II trial of docetaxel, estramustine and low dose hydrocortisone (CALGB 9780). A secondary obj ... Full text Link to item Cite

The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

Journal Article Clin Cancer Res · March 2001 Featured Publication The purpose of this study was to define the prognostic value of a group of molecular tumor markers in a well-staged population of patients treated with trimodality therapy for esophageal cancer. The original pretreatment paraffin-embedded endoscopic esopha ... Link to item Cite

Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.

Journal Article Clin Lung Cancer · February 2001 Featured Publication The purpose of this study was to examine the safety and efficacy of carboplatin/etoposide/paclitaxel in patients with untreated stage IV non-small-cell lung cancer (NSCLC) and extensive small-cell lung cancer (SCLC). Carboplatin was administered intravenou ... Full text Link to item Cite

73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.

Journal Article J Clin Oncol · February 1, 2001 Featured Publication PURPOSE: To assess results with twice-daily high-dose radiotherapy (RT) for non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Between 1991 and 1998, 94 patients with unresectable NSCLC were prescribed > or = 73.6 Gy via accelerated fractionation. F ... Full text Link to item Cite

Social support as a buffer to the psychological impact of stressful life events in women with breast cancer.

Journal Article Cancer · January 15, 2001 Featured Publication BACKGROUND: Three theoretical models by which social support may influence the impact of stressful life events on cancer patients' psychological state were tested: 1) the additive model, in which social support and stressful life events each directly influ ... Full text Link to item Cite

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Journal Article Oncologist · 2001 Featured Publication The maximum tolerated dose of conformal radiation therapy delivered at 1.6 Gy bid is being assessed in patients with unresectable stage IIB-IIIB non-small cell lung cancer who have been treated with induction regimens consisting of carboplatin plus paclita ... Full text Link to item Cite

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal Article Lung Cancer · 2001 Featured Publication Several studies have suggested that non-small cell lung cancer (NSCLC) patients whose tumors have neuroendocrine (NE) features may be more responsive to chemotherapy. In addition, increased expression of p53 and HER2 may confer relative chemotherapy resist ... Full text Link to item Cite

Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.

Journal Article Health Psychol · January 2001 Featured Publication Persistent symptoms of nausea, distress, and vomiting triggered by reminders of cancer treatment were examined among 273 Hodgkin's disease survivors, 1 to 20 years posttreatment. Prevalence rates were high for distress and nausea but low for vomiting. Retr ... Link to item Cite

Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.

Journal Article Anticancer Res · 2001 Featured Publication BACKGROUND: CA 125 and CEA are valuable serum tumor markers that can be used to monitor response to therapy in patients with various solid tumors. Systemic studies of CA125 and CEA have not been evaluated in lung cancer. In this study, we report the serum ... Link to item Cite

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

Journal Article Lung Cancer · 2001 Featured Publication PURPOSE: The CALGB conducted a phase II multicenter trial to evaluate the activity of gemcitabine in malignant mesothelioma (CALGB protocol 9530). PATIENTS AND METHODS: Seventeen patients were accrued between February 1996 and May 1996 and received gemcita ... Full text Link to item Cite

Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.

Journal Article Lung Cancer · 2001 Featured Publication PURPOSE: To correlate FDG activity on PET with the expression of glucose transporter proteins Glut-1 and Glut-3 in patients with early stage non-small cell lung cancer (NSCLC). METHODS: Over a 5 year period, all patients with a PET scan and clinical stage ... Full text Link to item Cite

Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities.

Journal Article Cancer Detect Prev · 2001 Featured Publication Our purpose was to determine whether peripheral blood biomarkers MUC1 and CK19 could be used to complement imaging studies in differentiating benign from malignant indeterminate pulmonary nodules or masses detected on computed tomography CT. One hundred an ... Link to item Cite

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Journal Article J Clin Oncol · November 15, 2000 Featured Publication PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine-131 ((131)I)-labeled 81C6 antitenascin monoclonal antibody (mAb) administered clinically into surgically created resection cavities (SCRCs) in malignant glioma patients and to identify any ob ... Full text Link to item Cite

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Journal Article J Clin Oncol · October 15, 2000 Featured Publication PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy involves the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT), which removes chloroethylation or methylation damage from the O(6) position of guanine. O(6)-benzylguanine ... Full text Link to item Cite

Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer.

Journal Article Chest · June 2000 Featured Publication OBJECTIVE: The purpose of this study was to determine the relationship between tumor size and survival in patients with stage IA non-small cell lung cancer (non-small cell lung cancer; ie, lesions < 3 cm). METHOD: Five hundred ten patients with pathologic ... Full text Link to item Cite

Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.

Journal Article Radiology · June 2000 Featured Publication PURPOSE: To determine the accuracy of 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in the evaluation of regional lymph nodes in patients with stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Imaging and ... Full text Link to item Cite

Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

Journal Article Lung Cancer · April 2000 Featured Publication In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were ... Full text Link to item Cite

Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.

Journal Article AJR Am J Roentgenol · March 2000 Featured Publication OBJECTIVE: We determined the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for patients with treated lung cancer. MATERIALS AND METHODS: We examined patients who underwent FDG PET after first-line treatment for non-sma ... Full text Link to item Cite

Molecular biologic substaging of stage I lung cancer according to gender and histology.

Journal Article Ann Thorac Surg · March 2000 Featured Publication BACKGROUND: This study is designed to assess molecular biologic substaging according to gender and histology in patients with stage I non-small cell lung cancer (NSCLC). METHODS: Pathologic specimens were collected from 408 consecutive patients after compl ... Full text Link to item Cite

Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.

Journal Article Int J Radiat Oncol Biol Phys · March 1, 2000 Featured Publication PURPOSE: The objective of this study was to perform the dosimetry and evaluate the dose-response relationships in newly diagnosed patients with malignant brain tumors treated by direct injections of (131)I-labeled 81C6 monoclonal antibody (MAb) into surgic ... Full text Link to item Cite

Sclerotherapy for malignant pleural effusions

Journal Article Pneumologie · December 1, 1999 Cite

Sclerotherapy for malignant pleural effusions

Journal Article Pneumologie · December 1, 1999 Cite

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.

Journal Article Cancer · November 15, 1999 Featured Publication BACKGROUND: The Cancer and Leukemia Group B (CALGB) conducted sequential Phase II multicenter trials to evaluate the activity of edatrexate alone (E) or with leucovorin rescue (EL) in patients with malignant pleural mesothelioma (CALGB Protocol 9131). METH ... Link to item Cite

Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer.

Journal Article AJR Am J Roentgenol · November 1999 Featured Publication OBJECTIVE: The purpose of this study was to determine the incidence and clinical significance of thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation for treatment of metastatic or high-risk primary (with at least four p ... Full text Link to item Cite

Staging non-small cell lung cancer with whole-body PET.

Journal Article Radiology · September 1999 Featured Publication PURPOSE: To compare the accuracies of whole-body 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and conventional imaging (thoracic computed tomography [CT], bone scintigraphy, and brain CT or magnetic resonance [MR] imagin ... Full text Link to item Cite

Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

Journal Article Int J Radiat Oncol Biol Phys · August 1, 1999 Featured Publication PURPOSE: To evaluate the incidence, severity, and clinical/dosimetric predictors of acute and chronic esophageal toxicities in patients with non-small cell lung cancer (NSCLC) treated with high-dose conformal thoracic radiation. METHODS AND MATERIALS: Nine ... Full text Link to item Cite

Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax.

Journal Article Radiology · July 1999 Featured Publication PURPOSE: To determine whether contrast material-enhanced helical computed tomography (CT) of the thorax and upper abdomen changes the tumor stage and management compared with nonenhanced helical CT in patients with newly diagnosed lung cancer. MATERIALS AN ... Full text Link to item Cite

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

Journal Article Ann Oncol · May 1999 Featured Publication BACKGROUND: New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy. PATIENTS AND ... Full text Link to item Cite

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

Journal Article J Thorac Cardiovasc Surg · April 1999 Featured Publication OBJECTIVE: The standard treatment of patients with stage I non-small cell lung cancer is resection of the primary tumor; however, the recurrence rate is 28% to 45%. This study evaluates a panel of molecular markers in a large population of patients with st ... Full text Link to item Cite

Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?

Journal Article Cancer · January 15, 1999 Featured Publication BACKGROUND: Several studies have recently reported on the importance of quality of life (QOL) in predicting the survival of patients with lung carcinoma. To confirm these reports, the relationship between survival and QOL, as measured by the European Organ ... Full text Link to item Cite

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.

Journal Article J Clin Oncol · January 1999 Featured Publication PURPOSE: To determine whether the administration of carboplatin concurrently with radiation treatment improves survival in patients with inoperable stage III non-small-cell lung cancer. PATIENTS AND METHODS: Two hundred eighty-three patients with inoperabl ... Full text Link to item Cite

Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression.

Journal Article Cancer · January 1, 1999 Featured Publication BACKGROUND: Tumor cell motility is an important characteristic that facilitates the multistep process of tumor metastasis. Rac, ABP-280, and gelsolin are proteins that interact with actin and are important in cell motility. METHODS: The authors studied a c ... Full text Link to item Cite

Sphincter-sparing treatment for distal rectal adenocarcinoma.

Journal Article Ann Surg Oncol · 1999 Featured Publication BACKGROUND: Studies suggest that the anal sphincter can be preserved in some patients with distal rectal adenocarcinoma (DRA), but this has not been validated in any prospective multi-institutional trial. METHODS: To test the hypothesis that the anal sphin ... Full text Link to item Cite

Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis.

Journal Article Radiology · January 1999 Featured Publication Thirty-two patients with a known primary malignancy and a symptomatic malignant pleural effusion underwent small-bore-catheter thoracostomy and talc pleurodesis. Twenty-three patients (72%) had a complete response; four (12%), a partial response; and five ... Full text Link to item Cite

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

Journal Article J Clin Oncol · November 1998 Featured Publication PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy is the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT), which removes chlorethylation or methylation damage from the O6-position of guanine. O6-benzylguanine (O6-BG) is an ... Full text Link to item Cite

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.

Journal Article J Clin Oncol · November 1998 Featured Publication PURPOSE: An improvement in radiation dose schedule is necessary to increase local tumor control and survival in limited-stage small-cell lung cancer. The goal of this study was to determine the maximum-tolerated dose (MTD) of radiation (RT) in both standar ... Full text Link to item Cite

A design alternative for two-stage, phase II, multicenter cancer clinical trials.

Journal Article Control Clin Trials · October 1998 Featured Publication Data are reviewed upon completion of patient accrual to the first stage of a two-stage phase II cancer clinical trial and prior to initiating accrual on the second stage. Often accrual must be suspended while the data from the first stage are collected and ... Full text Link to item Cite

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

Journal Article Cancer · September 1, 1998 Featured Publication BACKGROUND: A fundamental property of malignant tumors is increased glucose metabolism, which can be estimated by imaging the glucose analog fluorodeoxyglucose (FDG). The aim of this study was to determine whether FDG uptake in lung carcinoma, as measured ... Link to item Cite

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal Article Lung Cancer · September 1998 Featured Publication Several studies have suggested that biochemical or molecular markers examined in non-small cell lung cancer carry prognostic or treatment response information. Non-small cell lung cancer patients whose tumors have neuroendocrine (NE) features may be more r ... Full text Link to item Cite

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

Journal Article J Interferon Cytokine Res · August 1998 Featured Publication A previous phase II study (CALGB 9132) of etoposide/cisplatin + rG-CSF in patients with advanced non-small cell lung cancer (NSCLC) showed a marked difference in the absolute neutrophil count (ANC) nadirs between courses 1 and 2. Median ANC nadirs for cour ... Full text Link to item Cite

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

Journal Article J Clin Oncol · July 1998 Featured Publication PURPOSE: To provide a 10-year update of the experience of the Cancer and Leukemia Group B (CALGB) in the addition of thoracic radiation therapy to chemotherapy in limited-stage small-cell lung cancer. PATIENTS AND METHODS: Three hundred ninety-nine patient ... Full text Link to item Cite

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

Journal Article J Clin Oncol · July 1998 Featured Publication PURPOSE: To retrospectively construct a comprehensive multivariate model of cancer recurrence and to design a molecular pathologic substaging system in stage I non-small-cell lung cancer (NSCLC). METHODS: All patients with stage I NSCLC resected at Brigham ... Full text Link to item Cite

Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

Journal Article J Clin Oncol · June 1998 Featured Publication PURPOSE: To determine the maximum-tolerated dose (MTD) of iodine 131 (131I)-labeled 81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection cavities (SCRCs) and to identify any objective responses to this treatment. METHODS ... Full text Link to item Cite

Cytologically proved malignant pleural effusions: distribution of transudates and exudates.

Journal Article Chest · May 1998 Featured Publication PURPOSE: This study attempts to determine the distribution of transudates vs exudates in pathologically proved malignant pleural effusions and the necessity for cytologic studies in patients with a transudative effusion. MATERIALS AND METHODS: A retrospect ... Full text Link to item Cite

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

Journal Article J Clin Oncol · May 1998 Featured Publication PURPOSE: The current study assessed the psychologic and neuropsychologic functioning of patients with small-cell lung cancer who were randomized in a large clinical trial to receive intensive doxorubicin, cyclophosphamide, etoposide (ACE)/cisplatin, cyclop ... Full text Link to item Cite

Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.

Journal Article Bone Marrow Transplant · May 1998 Featured Publication We attempted to administer PEG-L-asparaginase (PEG-L-A) following hematologic recovery to 38 patients undergoing autologous or allogeneic marrow transplantation for acute lymphoblastic leukemia (ALL). Twenty-four patients (12 of 22 receiving allogeneic and ... Full text Link to item Cite

Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage.

Journal Article Chest · May 1998 Featured Publication BACKGROUND: Malignant pleural effusions are a common problem for patients with metastatic disease. Most patients are treated with tube thoracostomy and sclerotherapy, although there remains no standard approach. The purpose of this study was to compare the ... Full text Link to item Cite

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

Journal Article Cancer · April 15, 1998 Featured Publication BACKGROUND: In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of patients with advanced, previously untreated mesothelioma, dihydro-5-azacytidine (DHAC) demonstrated a 17% response rate, including 1 complete response, with only mild myelosuppre ... Link to item Cite

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

Journal Article Chest · March 1998 Featured Publication PURPOSE: To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB). PATIENTS AND METHODS: Between June 1984 and September 199 ... Full text Link to item Cite

Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.

Journal Article Ann Oncol · March 1998 Featured Publication BACKGROUND: The purpose of this study was to compare the long-term psychosocial adaptation of Hodgkin's disease and adult acute leukemia survivors. PATIENTS AND METHODS: Two hundred seventy-three Hodgkin's disease (HD) and 206 adult acute leukemia (AL) sur ... Full text Link to item Cite

A review of chemotherapy trials for malignant mesothelioma.

Journal Article Chest · January 1998 Featured Publication Treatment of malignant pleural mesothelioma continues to be frustrating regardless of the modality employed. Numerous trials of chemotherapeutic agents have been performed, but until recently, these studies were small and subject to inaccuracies of disease ... Full text Link to item Cite

Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

Journal Article Lung Cancer · January 1998 Featured Publication In a prior Cancer and Leukemia Group B (CALGB), 16% of a small cohort of patients with extensive small call lung cancer who had failed to obtain a complete remission with chemotherapy did obtain a complete remission after therapy with interleukin-2 (IL-2). ... Full text Link to item Cite

Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress.

Journal Article Cancer · November 15, 1997 Featured Publication BACKGROUND: To identify predictors of psychosocial adjustment for survivors of adult acute leukemia, the adaptation of 206 survivors (77% with acute myelogenous leukemia, and 23% with acute lymphocytic leukemia) treated on any of 13 Cancer and Leukemia Gro ... Full text Link to item Cite

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.

Journal Article J Clin Oncol · November 1997 Featured Publication PURPOSE: Studies by the Veterans Administration Cooperative Studies Program and Cancer and Leukemia Group B (CALGB) suggested that the addition of warfarin to chemotherapy might enhance response and/or survival in small-cell lung cancer (SCLC). This random ... Full text Link to item Cite

A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.

Journal Article Control Clin Trials · August 1997 Featured Publication A quality of life (QOL) endpoint supplemented standard clinical endpoints of survival, tumor response, and toxicity in a double-blind study conducted by the Cancer and Leukemia Group B (CALGB) where 291 patients with advanced non-small cell lung cancer (NS ... Full text Link to item Cite

Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer

Journal Article Seminars in Oncology · July 15, 1997 Chemotherapy has been shown to prolong the survival of patients with stage III non-small cell lung cancer. In particular, cisplatin and vinblastine administered before definitive radiotherapy results in a significant prolongation of median survival and inc ... Cite

Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.

Journal Article Semin Oncol · June 1997 Featured Publication Chemotherapy has been shown to prolong the survival of patients with stage III non-small cell lung cancer. In particular, cisplatin and vinblastine administered before definitive radiotherapy results in a significant prolongation of median survival and inc ... Link to item Cite

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

Journal Article Cancer · June 1, 1997 Featured Publication BACKGROUND: Malignant mesothelioma is a disease that is refractory to chemotherapy. Therefore, the objective of this multi-institutional, cooperative group Phase II trial was to determine the efficacy of dihydro-5-azacytidine (DHAC), a pyrimidine analogue, ... Full text Link to item Cite

High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.

Journal Article J Clin Oncol · May 1997 Featured Publication PURPOSE: We treated 49 patients with recurrent or poor-prognosis CNS malignancies with high-dose chemotherapy regimens followed by autologous marrow rescue with or without peripheral-blood stem-cell augmentation to determine the toxicity of and event-free ... Full text Link to item Cite

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.

Journal Article AJR Am J Roentgenol · May 1997 Featured Publication OBJECTIVE: The purpose of this study was to assess the usefulness of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) when differentiating benign from metastatic adrenal masses in patients with bronchogenic carcinoma. SUBJECTS AND METHO ... Full text Link to item Cite

Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).

Journal Article Am J Clin Oncol · February 1997 Featured Publication The maximum tolerated dose (MTD) of etoposide and carboplatin without growth factor support was previously defined by Cancer and Leukemia Group B (CALGB) as 200 and 125 mg/m2/day x 3, respectively, given every 28 days to previously untreated patients who h ... Full text Link to item Cite

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

Journal Article J Natl Cancer Inst · September 4, 1996 Featured Publication BACKGROUND: For many years, high dose radiation therapy was the standard treatment for patients with locally or regionally advanced non-small-cell lung cancer (NSCLC), despite a 5-year survival rate of only 3%-10% following such therapy. From May 1984 thro ... Full text Link to item Cite

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.

Journal Article Lung Cancer · September 1996 Featured Publication Patients with untreated extensive small cell lung cancer (SCLC) with CALGB performance scores 0-2 were treated with etoposide 200 mg/m2/day on days 1-3 and cisplatin doses of 20, 30, or 35 mg/m2/day days 1-3 in a Phase I/II format. Of the nine patients tre ... Full text Link to item Cite

Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Journal Article Cancer · June 1, 1996 Featured Publication BACKGROUND: The impact of sequential trimodality therapy on the pattern of first site disease failure in pathologic Stage IIIA (N2) nonsmall cell lung carcinoma (NSCLC) was analyzed. METHODS: Seventy-four eligible patients with histologically documented St ... Full text Link to item Cite

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

Journal Article Clin Cancer Res · June 1996 Featured Publication We aimed to determine the maximum tolerated dose (MTD) of 131I-labeled 81C6 in patients with leptomeningeal neoplasms or brain tumor resection cavities with subarachnoid communication and to identify any objective responses. 81C6 is a murine IgG monoclonal ... Link to item Cite

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

Journal Article Lung Cancer · June 1996 Featured Publication This Phase II study was designed to determine the efficacy of two chemotherapy regimens with G-CSF support for patients with advanced non-small cell lung cancer (NSCLC). One-hundred and one patients with Stage IIIB or IV NSCLC and performance status 0-1 we ... Full text Link to item Cite

Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B.

Journal Article J Natl Cancer Inst · May 15, 1996 Featured Publication BACKGROUND: The possible link between psychological factors and length of cancer survival has generated a literature of contradictory findings. Associations usually have not been found when general psychological symptoms are assessed. Associations usually ... Full text Link to item Cite

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.

Journal Article Ann Thorac Surg · May 1996 Featured Publication BACKGROUND: Although complete surgical resection remains the primary treatment for localized stage I non-small cell lung cancer, the cancer recurrence rate is 25% to 40%. If one could identify, a subset of patients using molecular factors that contribute t ... Full text Link to item Cite

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.

Journal Article Int J Radiat Oncol Biol Phys · March 1, 1996 Featured Publication PURPOSE: This study was designed to evaluate strategies to overcome the resistance of anaplastic gliomas of the brain to external beam radiotherapy (ERT) plus carmustine (BCNU). Patients were > or = 15 years of age, had a histologic diagnosis of malignant ... Full text Link to item Cite

Interruptions of modest dose once-daily (QD) thoracic radiotherapy (TRT) do not correlate with outcome in limited small cell lung cancer (L-SCLC): Analysis of CALGB 9235

Journal Article Cancer Journal · January 1, 1996 Background: TRT dose intensity (dose/time) may be an important variable in the treatment of L-SCLC. A prospective trial demonstrated improved survival (OS) for patients receiving accelerated TRT, and retrospective data suggests TRT interruptions (TRT-1) ne ... Full text Cite

Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma.

Journal Article Chest · December 1995 Featured Publication PURPOSE: To assess the role of positron emission tomographic (PET) imaging with 18-fluoro-2-deoxyglucose (18FDG) in detecting thoracic lymph node metastases in patients with bronchogenic carcinoma. MATERIALS AND METHODS: Over a 2-year period, any patient p ... Full text Link to item Cite

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.

Journal Article Lung Cancer · December 1995 Featured Publication A multi-institutional cooperative group trial was undertaken by the Cancer and Leukemia Group B (CALGB) to evaluate the efficacy of the combination of cisplatin and intravenous etoposide for the treatment of metastatic or recurrent non-small cell lung canc ... Full text Link to item Cite

Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.

Journal Article Clin Cancer Res · December 1995 Featured Publication LMB-1 (B3-LysPE38) is an immunotoxin composed of the tumor-reactive monoclonal antibody B3 and a genetically engineered form of Pseudomonas exotoxin. Monoclonal antibody B3 reacts with a carbohydrate epitope that is found on a number of solid tumors (e.g., ... Link to item Cite

The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables.

Journal Article Stat Med · October 15, 1995 Featured Publication We incorporate a cubic spline function where the tails are linearly constrained, as the baseline hazard, into the proportional hazards model. We show estimation of covariable coefficients and survival probabilities with this model to be as efficient statis ... Full text Link to item Cite

Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.

Journal Article Cancer · September 1, 1995 Featured Publication BACKGROUND: Nonsmall cell lung cancer (NSCLC) has become the leading cause of cancer-related deaths in women and men in the United States, with more than 157,000 estimated deaths in 1995. Surgical resection remains the mainstay of therapy in Stage I and II ... Full text Link to item Cite

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

Journal Article J Clin Oncol · August 1995 Featured Publication PURPOSE: This was a randomized phase III study to test the schedule dependency of etoposide given as a conventional 3-day intravenous (IV) regimen versus a prolonged 21-day oral regimen for extensive-stage small-cell lung cancer (SCLC). Both regimens conta ... Full text Link to item Cite

Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.

Journal Article Clin Cancer Res · June 1995 Featured Publication Historical information and pathological material from 150 consecutive patients with localized adenocarcinoma of the lung was collected to evaluate oncogene expression of erbB-2 and p53, and erbB-2 gene amplification. Pathological material after resection w ... Link to item Cite

Placebo-controlled randomized study of hydrazine sulfate in lung cancer.

Journal Article J Clin Oncol · June 1995 Featured Publication Full text Link to item Cite

Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Journal Article Proc Natl Acad Sci U S A · March 28, 1995 Featured Publication LMB-7 [B3(Fv)-PE38] is a single-chain immunotoxin constructed from the murine monoclonal antibody B3 and a truncated from of Pseudomonas exotoxin PE38. Antibody B3 recognizes a carbohydrate epitope found on solid tumors that frequently invade the intrathec ... Full text Link to item Cite

Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.

Journal Article J Thorac Cardiovasc Surg · March 1995 Featured Publication From October 1989 to February 1992, 74 patients with mediastinoscopically staged IIIA (N2) non-small-cell lung cancer from 30 CALGB-affiliated hospitals received two cycles of preresectional cisplatin and vinblastine chemotherapy. Patients with responsive ... Full text Link to item Cite

A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB.

Journal Article Am J Clin Oncol · February 1995 Featured Publication A total of 71 patients with extensive small cell lung cancer were enrolled in CALGB study 8733. Chemotherapy was administered with cisplatin 33 mg/m2, i.v. infusion days 1-3, doxorubicin 45 mg/m2 i.v. day 1, cyclophosphamide 800 mg/m2 i.v. day 1, and etopo ... Full text Link to item Cite

A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.

Journal Article Cancer Res · January 1, 1995 Featured Publication In order to construct a multivariate model for predicting early recurrence and cancer death for patients with stage I non-small cell lung cancer, 271 consecutive patients (mean age, 63 +/- 8 years) who were diagnosed, treated, and followed at one instituti ... Link to item Cite

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.

Journal Article Cancer · August 15, 1994 Featured Publication BACKGROUND: The purpose of this study was to assess the ability of administering to patients induction chemotherapy with carboplatin and etoposide (VP-16), followed by full-course radiation therapy and weekly carboplatin with tolerable toxicity as preopera ... Full text Link to item Cite

Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636.

Journal Article Int J Radiat Oncol Biol Phys · July 30, 1994 Featured Publication PURPOSE: A pilot trial testing the feasibility of chemotherapy and radiotherapy was done in Stage III A and B nonsmall cell lung cancer. The schedule was designed to be consistent with the laboratory model of Looney and Hopkins. METHODS AND MATERIALS: Trea ... Full text Link to item Cite

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

Journal Article J Clin Oncol · July 1994 Featured Publication PURPOSE: Folic acid antagonists are reported to have activity against mesothelioma. The Cancer and Leukemia Group B (CALGB) undertook this phase II study of the new antifolate, trimetrexate (TMTX), to evaluate its response rate and toxicity in chemotherapy ... Full text Link to item Cite

Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience.

Journal Article Semin Oncol · June 1994 Featured Publication The Cancer and Leukemia Group B (CALGB) is studying nonoperative management in two subgroups of patients with advanced non-small cell lung cancer. In patients with regional disease, primarily those with bulky N2 or T4 disease or those with contralateral me ... Link to item Cite

Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.

Journal Article J Clin Oncol · June 1994 Featured Publication PURPOSE: To assess the chemotherapy regimen of cisplatin, vinblastine, and hydrazine sulfate administered to patients with non-small-cell lung cancer (NSCLC) in a randomized, placebo-controlled double-blind phase III study. PATIENTS AND METHODS: Between Ju ... Full text Link to item Cite

A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study.

Journal Article J Immunother Emphasis Tumor Immunol · April 1994 Featured Publication Forty-one patients with advanced non-small cell lung cancer (NSCLC) were entered into a phase II study of high dose recombinant interferon (rIFN)-beta. Patients received intravenous (i.v.) rIFN-beta on a Monday, Wednesday, Friday schedule with a weekly dos ... Full text Link to item Cite

Alterations of the TP53 gene in human gliomas.

Journal Article Cancer Res · March 1, 1994 Featured Publication Glial tumors of all grades and histological types from 72 adults and 48 children were analyzed for mutations of the TP53 gene, loss of heterozygosity (LOH) for 17p, and accumulation of TP53 protein to determine whether the incidence and type of TP53 altera ... Link to item Cite

A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B.

Journal Article Cancer Invest · 1994 Featured Publication The purpose of this study was to determine the feasibility of additional chemotherapy beyond 5 weeks of vinblastine-cisplatin followed by radiation therapy for patients with stage III non-small cell lung cancer. In this randomized phase II trial, the goal ... Full text Link to item Cite

Nonoperative management of non-small cell lung cancer: The current Cancer and Leukemia Group B experience

Journal Article Seminars in Oncology · January 1, 1994 The Cancer and Leukemia Group B (CALGB) is studying nonoperative management in two subgroups of patients with advanced non-small cell lung cancer. In patients with regional disease, primarily those with bulky N2 or T4 disease or those with contralateral me ... Cite

Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.

Journal Article J Clin Oncol · November 1993 Featured Publication PURPOSE: The impact of the side effects of megestrol acetate on the quality of life of noncachectic women with advanced breast cancer was studied in a dose-response clinical trial of the Cancer and Leukemia Group B (CALGB 8741). Side effects of appetite in ... Full text Link to item Cite

An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.

Journal Article Am J Clin Oncol · August 1993 Featured Publication The CNS Cancer Consortium has conducted a phase III study comparing diaziquone (AZQ) with carmustine (BCNU) in the treatment of adults with primary anaplastic glial brain tumors. Patients eligible for this study were 18 years of age or older at the time of ... Full text Link to item Cite

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

Journal Article J Clin Oncol · August 1993 Featured Publication PURPOSE: The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II multicenter trial to evaluate the activity of two cisplatin-containing regimens (cisplatin and mitomycin [CM], or cisplatin and doxorubicin [CD]) in patients with malignant pl ... Full text Link to item Cite

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.

Journal Article Cancer · July 1, 1993 Featured Publication BACKGROUND: This Phase I study was designed to determine the maximum tolerated dose of ifosfamide-mesna with a fixed dose of cisplatin without growth factor or hematopoietic precursor support. METHODS: Twenty-five patients with previously untreated advance ... Full text Link to item Cite

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

Journal Article J Natl Cancer Inst · February 17, 1993 Featured Publication BACKGROUND: Chemotherapy may induce overall (complete plus partial) response rates of more than 50% and complete response rates up to 25% in extensive small-cell lung cancer (stage IIIB or IV), but survival is generally limited to 8-12 months. Interleukin- ... Full text Link to item Cite

Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

Journal Article J Clin Oncol · January 1993 Featured Publication PURPOSE: We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy. Its purpose was to compare the efficacy of AZ ... Full text Link to item Cite

Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.

Journal Article Ann Oncol · November 1992 Featured Publication This randomized phase II study was designed to evaluate the activity of intravenous 6-thioguanine (6-TG) as a single agent and the combination of cisplatin and 5-fluorouracil (5-Fu) modulated by oral leucovorin (PFL) in patients with advanced non-small cel ... Full text Link to item Cite

Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B.

Journal Article Am J Clin Oncol · October 1992 Featured Publication From April 2 to July 9, 1989, Cancer and Leukemia Group B (CALGB) conducted a Phase II study of etoposide and carboplatin in advanced (AJC Stage IIIb-IV) non-small-cell lung cancer (NSCLC) patients whose performance status (PS) was 0-2. The combination was ... Full text Link to item Cite

Angiographic follow-up after internal mammary artery graft angioplasty.

Journal Article Am J Cardiol · August 1, 1992 Featured Publication Full text Link to item Cite

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.

Journal Article J Clin Oncol · August 1992 Featured Publication PURPOSE: This phase II trial was designed to evaluate the feasibility, toxicity, response rates, and survival for neoadjuvant chemotherapy and radiotherapy (RT) followed by surgical resection in newly diagnosed patients with surgically staged IIIA non-smal ... Full text Link to item Cite

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.

Journal Article Cancer Res · May 1, 1992 Featured Publication 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) resistance may be mediated by repair of chloroethylated guanine before stable cross-linking occurs. Guanine adducts may be repaired by the enzyme O6-alkylguanine-DNA alkyltransferase (O6-AGAT). Such repair irreve ... Link to item Cite

Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas.

Journal Article Neurology · November 1991 Featured Publication Stereotactic biopsy of CNS tumors provides a small amount of tissue for pathologic diagnosis. This potentially leads to inaccurate grading of gliomas because of their histologic heterogeneity. We compared histologic diagnoses in a consecutive series of 329 ... Full text Link to item Cite

Relation between p53 overexpression and established prognostic factors in breast cancer.

Journal Article Surgery · August 1991 Featured Publication The nuclear phosphoprotein p53 is expressed in all normal cells and appears to function in cell cycle regulation. Abnormally high levels of the protein are found in many different types of cancer. In breast carcinoma overexpression of p53 is associated wit ... Link to item Cite

Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.

Journal Article Ann Neurol · April 1991 Featured Publication As aggressive neurosurgery and adjuvant therapy have become standard care for most patients with primary central nervous system (CNS) tumors, limitations of posttreatment neuroimaging techniques have become more apparent. Interpretation of computed cranial ... Full text Link to item Cite

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study.

Journal Article Cancer Chemother Pharmacol · 1991 Featured Publication Between July 2, 1987, and August 21, 1987, Cancer and Leukemia Group B (CALGB) conducted a phase II evaluation of carboplatin (CBDCA) and vinblastine (VBL) in advanced non-small-cell lung cancer. Of the 58 patients who entered the study, 55 were eligible a ... Full text Link to item Cite

The restricted cubic spline hazard model

Journal Article Communications in Statistics - Theory and Methods · January 1, 1990 A cubic spline hazard model where the tails are linearly constrained (Stone and Koo, 1985) has considerable flexibility in describing data which has been generated from distributions having a variety of hazard function shapes. This model is as efficient as ... Full text Cite